PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2019

10-14 April 2019 Vienna

N. Poster

Poster title

Applicant name

Status


THU-001	Identifying intrahepatic lymphocyte permutations in active untreated, resistant and treated autoimmune hepatitis	Gautham Appanna	Received

LBP-001	In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys	Fredrik berg	Received

SAT-001	Validity of urinary bio markers and cardiac echo in diagnosis of acute kidney injury in patients with liver cirrhosis	Amany Abbasy	Received

FRI-001	The PBC-10: A validated short clinic symptom screening tool for primary biliary cholangitis	Laith Alrubaiy	Received

SAT-002	Lusutrombopag is a safe treatment option for thrombocytopenia in patients with chronic liver disease undergoing an invasive procedure: Pooled safety analysis from 3 studies	Nezam Afdhal	Received

FRI-002	Sustained remission after treatment withdrawal in autoimmune hepatitis : A multicenter retrospective study	Gérard THIEFIN	Received

LBP-002	Association between HBsAg loss and long-term clinical outcome in chronic hepatitis B: a systematic review and meta-analysis analysis	Ryan Anderson	Received

THU-002	Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis	Johannes R Hov	Received

THU-003	European multicenter validation of autoantibodies against huntingtin-interacting protein 1-related protein for the diagnosis of autoimmune hepatitis in adults	Bastian Engel	Received

LBP-003	LPCN 1144, an Androgen Receptor Agonist Targeted for NASH, Reduces Liver Fat and Key Serum Biomarkers	Kilyoung Kim	Received

SAT-003	Real-world data demonstrate safety and effectiveness of lusutrombopag in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures: Interim analysis	Nezam Afdhal	Received

FRI-003	Early response to corticosteroid treatment supports differentiation of drug-induced liver injury and autoimmune hepatitis	Andreas Benesic	Received

FRI-004	Cirrhosis status at diagnosis, non-Caucasian descent, treatment response and age determine long term survival in autoimmune hepatitis	Maaike Biewenga	Received

SAT-004	Bacterial translocation in patients with liver cirrhosis and variceal bleeding	Christos Triantos	Received

THU-004	Lactobacillus rhamnosus GG prevents liver fibrosis through intestinal FXR/FGF15-mediated inhibition of bile acid synthesis and the increase of bile acid excretion in mice	Wenke Feng	Received

LBP-004	Investigation of synbiotic treatment in non alcoholic fatty liver disease (NAFLD): Results of the INSYTE study	Chris Byrne	Received

FRI-005	Characteristics and outcome of autoimmune hepatitis-primary biliary cholangitis and autoimmune hepatitis-primary sclerosing cholangitis overlap patients compared to autoimmune hepatitis patients	Maaike Biewenga	Received

SAT-005	Prognostic factors associated with mortality of acute variceal hemorrhage in cirrhotic patients : Multi-center results	Kuntapon Akkarachinores	Received

LBP-005	classification and mutation prediction based on liver cancer hisopathological images using deep learning	Mingyu Chen	Received

THU-005	Activation regulators of peripheral blood and intrahepatic T effector cells in autoimmune hepatitis	Pamela Filpe	Received

LBP-006	High Seroprotection Rates Achieved with Two Doses of Sci-B-Vac, a Third Generation Hepatitis B containing PreS1, PreS2 and S Antigens.	Francisco Diaz-Mitoma	Received

SAT-006	Efficacy of oral thrombopoietin receptor agonist lusutrombopag in chronic liver disease by underlying disease aetiology	Naim Alkhouri	Received

THU-006	Aberrant DNA methylation in bile accurately detects cholangiocarcinoma in patients with primary sclerosing cholangitis	Trine Folseraas	Received

FRI-006	Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis	Lars Bossen	Received

FRI-007	Serum markers of macrophage activation CD163 and Mannose receptor predict transplant-free survival in primary sclerosing cholangitis	Lars Bossen	Received

LBP-007	Association of pharmacogenomics and pharmacokinetics with antiviral activity of Pradefovir for treatment of chronic hepatitis B infection.	Qingmei Li	Received

SAT-007	Survival and risk factors of mortality after emergency transjugular intrahepatic portosystemic shunt for uncontrolled acute variceal bleeding caused by cirrhosis-related portal hypertension	Manon Allaire	Received

LBP-008	The Worlds Largest Hepatitis C Screening Program in Egypt	Magdi El-Serafy	Received

SAT-008	Quality of medical care measurement in hepatic cirrhosis outpatients: Is there room for improvement?	Alberto Amador	Received

FRI-008	Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study	Marco Carbone	Received

LBP-009	Liver humanization of Fah -/- /Rag2 -/- /Il2rg -/- NOD mice with human hepatocytes homozygous for M148I PNPLA3 allows the assessment of specific genotype contribution to NASH development in vivo.	Lander Foquet	Received

THU-009	High throughput RNA sequencing unravels pathways associated with cognitive deficit in primary billiary cholangitis	Lucy Gee	Received

SAT-009	Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis	Alberto Amador	Received

FRI-009	Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with prolonged predicted survival even in patients with incomplete biochemical improvements	Christophe Corpechot	Received

LBP-010	A structurally engineered fatty acid, icosabutate, rapidly normalises elevated plasma ALT and gamma-glutamyl transferase (GGT) concentrations in a study population at high risk of NAFLD/NASH	David Fraser	Received

SAT-010	Predictors of mortality in Child B cirrhotic patients with acute variceal bleeding	Alberto Amador	Received

FRI-010	Bezafibrate add-on therapy in high-risk primary biliary cholangitis is associated with an improvement of fibrometer and fibrometer-VCTE, two high-accuracy non-invasive fibrosis tests extensively validated in frequent chronic liver diseases	Christophe Corpechot	Received

THU-010	Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis	Alessio Gerussi	Received

LBP-011	Is it possible to successfully link migrants from low-income countries to HBV, HCV, and HIV services upon arrival in the European Union?	Jeffrey V Lazarus	Received

FRI-011	Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis	Laura Cristoferi	Received

THU-011	Cholecystectomy causes worsening of primary sclerosing cholangitis features in Abcb4 knockout mice	Ester Gonzalez-Sanchez	Received

SAT-011	Cirrhotic patients:Is there any role to malnutrition in predicting mortality?	Cátia Arieira	Received

FRI-012	Analysis of clinical and histological factors to differentiate autoimmune hepatitis of drug induced liver injury	Lidia Cuevas del Campo	Received

LBP-012	Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers	Edward Gane	Received

THU-012	Prevalence of autoimmune liver disease related autoantibodies in various non autoimmune liver diseases	Rakesh Kumar Jagdish	Received

SAT-012	Alterations in skin microbiota, serum bile acids and autotaxin modulate itching intensity in patients with cirrhosis	JASMOHAN BAJAJ	Received

THU-013	Investigating the potential immunomodulatory role of mesenchymal stromal cells in primary sclerosing cholangitis	Ashnila Janmohamed	Received

LBP-013	Effect of treatment of hepatitis B patients with tenofovir disoproxil or entecavir on risk of hepatocellular cancer death in a U.S. Cohort	Lora Rupp	Received

FRI-013	A combined blood and MR imaging risk score for monitoring liver inflammation in paediatric AIH	Andrea Dennis	Received

SAT-013	Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort	JASMOHAN BAJAJ	Received

THU-014	Primary sclerosing cholangitis-associated biliary neoplasia demonstrates a high inter- and intratumour heterogeneity	Eline Kamp	Received

LBP-014	Magnetic Resonance Biomarkers for Early Phase Steatohepatitis Clinical Trials: Short Term Evaluation in Adolescents, Transitoriness or Stability in Steatosis (STEATOSIS)	Nidhi Goyal	Received

SAT-014	Efficacy of rifaximin soluble solid dispersion in patients with early decompensated cirrhosis and a Conn score of 0: A post hoc analysis of a randomized, double-blind, placebo-controlled trial	Jasmohan Bajaj	Received

FRI-014	Diagnostic criteria for autoimmune hepatitis: what is a normal IgG?	Jessica Dyson	Received

FRI-015	Environmental triggering in primary biliary cholangitis: Disease risk relates to coal mining activity	Jessica Dyson	Received

LBP-015	Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis	Adria Juanola	Received

SAT-015	Sarcopenia is associated with a worst prognosis in cirrhotic patients in the context of liver transplantation	Chantal Bemeur	Received

THU-015	Mutational signatures during the neoplastic cascade towards cholangiocarcinoma in primary sclerosing cholangitis	Eline Kamp	Received

THU-016	Loss of signaling through the G-protein coupled bile acid receptor Tgr5 confers protection from fibrosis in the progressive cholangiopathy of Mdr2-/- mice	Nelson Matuschek	Received

LBP-016	Phase II trial to evaluate immunogenicity and safety of a new adjuvanted HBAI20 Hepatitis B vaccine in non-responders: BE RESPONDER.	zgr Koc	Received

SAT-016	Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites	Amine Benmassaoud	Received

FRI-017	High prevalence of possible PSC recurrence post transplant evaluated by protocol biopsies	Lise Katrine Engester	Received

LBP-017	Robust Mucosal-associated invariant T (MAIT) cell activation in response to interactions with primary human liver cell subsets	Martin Lett	Received

SAT-017	Anticoagulant effect of edoxaban in patients with cirrhosis: The POET study	Sarah Bos	Received

SAT-018	Relation of CT determined sarcopenia and anthropometry to serum C-reactive protein levels in patients with chronic liver disease	Sarah Brown	Received

LBP-018	Effect of Obeticholic Acid on Liver Function in Patients with Fibrosis due to NASH	Kjersti Swearingen	Received

THU-018	c-Jun N-terminal kinases act synergistically in hepatocytes to protect mice from cholestatic liver injury	Mohamed Ramadan Mohamed	Received

THU-019	Impact of metabolic stress on the pathogenesis of autoimmune liver disease in subjects bearing missense variant of negative immune regulator Lnk/Sh2b3	Taizo Mori	Received

LBP-019	NGM282 Promotes HDL Biogenesis and Transhepatic Cholesterol Efflux to Prevent Atherosclerosis in Mice	Lei Ling	Received

SAT-019	Minimal hepatic encephalopathy: Which test should we use in clinical practice?	Benjamin Buchard	Received

FRI-019	Readmission in hospitalized patients with autoimmune hepatitis in nationwide inpatient setting	Xiaowen Fan	Received

THU-020	Postprandial changes in the hepatic bile acid transport in healthy human subjects measured by 11C-CSar PET/CT	Nikolaj Worm rntoft	Received

SAT-020	Transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with ascites	Theresa Bucsics	Received

FRI-020	Identification of risk factors for histological progression with sequential liver biopsies in primary cholangitis patients	Yukihisa Fujinaga	Received

LBP-021	Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	Marlyn J. Mayo	Received

SAT-021	How to use platelets and liver stiffness to rule out esophageal varices needing treatment?	Paul Cales	Received

FRI-022	Characteristics of autoimmune hepatitis with acute presentation	Ana Gómez	Received

SAT-022	Transjugular intrahepatic portosystemic shunts is still an effective treatment for refractory variceal haemorrhage in patients with high MELD/ Child Pugh scores	Rigers Cama	Received

LBP-022	Outcome of 119 cirrhotic patients with splanchnic thrombosis: a single center real-life experience	Giorgia Micucci	Received

THU-022	CM-101- a Novel anti CCL24 monoclonal antibody reduces cholangiocytes proliferation in experimental cholestasis models	Neta Barashi	Received

FRI-023	Inadequate response to UDCA among PBC patients under routine care in the US: Rising serum bilirubin even in the normal range is a risk factor and subsequent clinical follow-up differs based on treatment response	Lora Rupp	Received

SAT-023	The lack of benefit of prophylactic transfusions of patients with cirrhosis and esophageal varices undergoing endoscopic variceal ligation	Andres Cardenas	Received

LBP-024	Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with non-alcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study	Danielle Emery	Received

SAT-024	Effect of acute kidney injury on long-term outcomes of spontaneous bacterial peritonitis in cirrhotics using ICA-AKI criteria	Ju-Yeon Cho	Received

FRI-024	Incidence and prevalence of autoimmune hepatitis in England 1997-2015. A population-based cohort study	Lisbet Grnbk	Received

THU-025	Pathway-analysis using datasets of GWAS and microarray identified IFNG as the most significant upstream-regulator in primary biliary cholangitis	Kazuko Ueno Ueno	Received

LBP-025	a phase 1 clinical trial of therapeutic vaccine t101 in chronic hepatitis b(chb) patients: a randomized, double-blind, placebo-controlled, single and multiple injections, dose escalation study	Xiaomin WANG	Received

FRI-025	Long-term outcome in autoimmune hepatitis: The second twenty years	Laura Harrison	Received

FRI-026	Long-term assessment of the effects of obeticholic acid in patients with primary biliary cholangitis on immune and inflammatory markers	Emily Plummer	Received

THU-026	Natural killer T cells promote cholestatic liver disease in bile duct ligated mice	Laura Valestrand	Received

LBP-026	Magnetically controlled capsule endoscopy as a noninvasive tool for risk stratification of gastroesophageal varices in compensated cirrhosis (CHESS1801): A prospective multicenter study	Xiaolong Qi	Received

SAT-026	Mid-arm circumference and triceps skinfold thickness independently predicts mortality in hospitalized patients with decompensated cirrhosis	Camila Saueressig	Received

THU-027	The human apical sodium dependent bile salt transporter (ASBT) activates a bile salt-induced defense in human cholangiocytes	Jorrit van Niekerk	Received

FRI-027	Serum bile acids significantly associate with the fibrogenesis biomarker Pro-C3: analysis of a randomized, placebo-controlled trial of NGM282 in patients with primary sclerosing cholangitis	Gideon Hirschfield	Received

SAT-027	Effects of propranolol on liver- and spleen-stiffness measured by MR-Elastography in patients with cirrhosis	Karen Vagner Danielsen	Received

LBP-027	Preliminary analysis of SuperDOT-C: A cluster randomised controlled trial of pharmacy-led versus conventional treatment for HCV positive patients receiving daily opioid substitution therapy - The Tayside sites	Andrew Radley	Received

SAT-028	Diabetes is associated with TIPS failure in cirrhotic patients with refractory ascites	Stella De Nicola	Received

THU-028	Gut derived bacteria, presented by liver dendritic cells can activate liver MAIT cells in primary sclerosing cholangitis	Suz Warner	Received

LBP-029	BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys	Moti Rosenstock	Received

THU-029	Interleukin 23 produced by hepatic monocyte-derived macrophages is essential for the development of primary biliary cholangitis	Ehud Zigmond	Received

SAT-029	Prediction of hepatic hydrothorax in cirrhosis patients with ascites	Thomas Deleuran	Received

FRI-029	Non-alcoholic fatty liver disease and steatohepatitis in autoimmune hepatitis: important player or innocent bystander?	Zachou Kalliopi	Received

FRI-030	Treatment choice and long-term prognosis for elderly PBC	Hiroteru Kamimura	Received

LBP-030	Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Nonalcoholic Steatohepatitis	Arun Sanyal	Received

SAT-030	Annual contrast-enhanced MRI is highly effective in the surveillance of hepatocellular carcinoma in cirrhotic patients	Coskun Ozer Demirtas	Received

THU-031	Hemorrhagic and thrombotic complications in critically patients with cirrhosis	William Bernal	Received

LBP-031	AXA1665, a novel composition of amino acids restores the dysregulated amino acid profile, lowers ammonia, and improves body composition and function in Child-Pugh class A and B subjects	Manu Chakravarthy	Received

SAT-031	Bleeding risk-scores for prediction of acute variceal bleeding outcome	marwa Elfayoumy	Received

FRI-031	Association between serum immunoglobulin G levels and intrahepatic plasmacytic gene signature in human autoimmune hepatitis	Atsumasa Komori	Received

FRI-032	Liver transplantation ameliorates chronic fatigue and improves quality of life in patients with primary sclerosing cholangitis	Marcin Krawczyk	Received

LBP-032	The Natural History of Ferroportin Disease First Results of the International, Multicenter EASL non-HFE Registry	Benedikt Schaefer	Received

THU-032	Peritoneal CD206 links macrophage heterogeneity in decompensated cirrhosis with outcome of spontaneous bacterial peritonitis	Tony Bruns	Received

SAT-032	Spleen to liver stiffness ratio significantly differs between ALD and HCV and predicts disease specific complications	Omar Elshaarawy	Received

THU-033	Impact of early Hemodynamic correction of AKI in acute on chronic liver failure patients with large ascites	Shreya Butala	Received

SAT-033	Body fat composition determines outcomes before and after liver transplantation in cirrhosis	Cornelius Engelmann	Received

LBP-033	Gelesis superabsorbent hydrogel prevents hepatic steatosis in a high fat diet-induced NAFLD pre-clinical model	Lauren Rautiola	Received

FRI-033	Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis	Emily Plummer	Received

LBP-034	Effect of Resistance Associated Substitutions on Retreatment of HCV infected patients with prior failure to Direct Acting Antiviral Therapy	David Smith	Received

FRI-034	Clinical phenotype of significantly elevated serum IgG4: Single center experience	Hadi Kuriry	Received

THU-034	Serum metabolite profiling predicts survival in patients with hepatitis B virus related acute-on-chronic liver failure	Ermei Chen	Received

SAT-034	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability	Chiara Formentin	Received

FRI-035	Clinical outcomes associated with additional fibrate treatment in UDCA-refractory PBC patients: A multicenter study	Cheol-Hyung Lee	Received

LBP-035	Kupffer cell development: A link between Notch signaling and LXRa	Wouter TJonck	Received

SAT-035	The negative impact of skeletal muscle volume loss during transarterial chemoembolization for hepatocellular carcinoma	Masashi Fujita	Received

THU-035	A shorter period of a subsequent episode of acute decompensation of cirrhosis predicts worse outcome: A single center experience	Po-Sung Chu	Received

SAT-036	Prognostic implications of encephalopathy to adequately define differentiated stages of decompensated cirrhosis	Marta García Guix	Received

THU-036	First description of the immune checkpoint receptor landscape in decompensated cirrhosis and ACLF	Douglas Corrigall	Received

LBP-036	Inhibition of glutamine synthetase in monocytes from patients with Acute-on-Chronic Liver Failure resuscitates their antibacterial and inflammatory capacity	Schallk Van der Merwe	Received

FRI-037	Change in lipids: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort	Stephanie Watkins	Received

THU-037	Soluble MAdCAM-1 as a novel marker of hepatic endothelial dysfunction in acutely decompensated cirrhosis	Jonathon Graham	Received

SAT-037	Applying the new nutritional screening and assessment algorithm to estimate malnutrition prevalence in Greek cirrhotic patients as suggested by the 2018 EASL nutritional guidelines for chronic liver disease	Maria Vasiliki Papageorgiou	Received

FRI-038	Good performance of the biochemical response criteria after three months of ursodeoxycholic acid treatment in patients with primary biliary cholangitis	Laura Patricia Llovet	Received

SAT-038	Lusutrombopag for treatment of thrombocytopenia in patients with chronic liver disease who are undergoing planned invasive procedures: pooled safety analysis of bleeding-related adverse events	Edoardo Giovanni Giannini	Received

THU-038	Fungal pneumonia in critically ill cirrhotics: Spectrum and outcomes	Pratibha Ramchandra Kale	Received

LBP-038	Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis	Robert Wong	Received

THU-039	LPS-induced upregulation of RANTES in a new mouse model of bacterial infection related acute-on-chronic liver injury	Ersin Karatayli	Received

FRI-039	Autoimmune hepatitis-related cirrhosis: The importance of treatment response and the utility of Baveno VI criteria	Laura Patricia Llovet	Received

SAT-039	The assessment of sarcopenia by quadriceps muscle ultrasound in patients with liver cirrhosis	Stefania Gioia	Received

SAT-040	Is spleen stiffness the new frontier for non-invasive assessment of portal hypertension?	Mauro Giuffrè	Received

LBP-040	Development of Oligonucleotide-Based miR-132 Antagonists for the Treatment of NASH	Shoutian Zhu	Received

FRI-040	Imaging and clinical correlations of macro regenerative nodules in primary sclerosing cholangitis	Beatrice Madrazo	Received

FRI-041	Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment	Lily Mao	Received

SAT-041	The adjunct of sarcopenia with MHE increases the 1 year risk of developing OHE	Rohit Gupta	Received

THU-041	Immune-metabolism disorder in progression of hepatitis B virus-related acute-on-chronic liver failure characterized by transcriptomics	Jun Li	Received

SAT-042	The stroop test is better at predicting the 6-month risk of developing overt hepatic encephalopathy compared to the PHES and CFF tests	Rohit Gupta	Received

THU-042	Hypoxia aggravates acute on chronic hepatitis through MIR-210 mediated macrophage autophagy impairment	Feifei Liu	Received

FRI-042	Prevalence and male/female ratio of autoimmune liver diseases are increasing over time in Japan: Hospital-based epidemiological study	Kosuke Matsumoto	Received

FRI-043	Primary biliary cholangitis - Autoimmune hepatitis overlap syndrome: Characteristics and response to obeticholic acid in TARGET-PBC, a diverse, large United States real-world cohort	Marlyn J. Mayo	Received

SAT-043	Is carvedilol better than propranolol in preventing variceal bleeding	Muhammad Farooq Hanif	Received

THU-043	Declining mortality of cirrhotic patients requiring admission to intensive care units for serious infections: A bi-national cohort study	Ammar Majeed	Received

THU-044	Cystatin C as a predictive biomarker of ACLF development and mortality on the liver transplant waiting list	Ezequiel Mauro	Received

SAT-044	Serum Myostatin in liver cirrhosis: A marker beyond malnutrition	Rewan Hanno	Received

FRI-045	Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survival	Carla Fiorella Murillo Perez	Received

SAT-045	Prevalence, type and risk factors of colonization by multidrug-resistant bacteria in a large series of patients with decompensated cirrhosis	Maria Hernandez-Tejero	Received

FRI-046	Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test	Carla Fiorella Murillo Perez	Received

THU-046	Implementation of acute kidney injury criteria to patients with acute-on-chronic liver failure: Characteristics of effect on outcomes	Laura Napoleone	Received

SAT-046	Clinical impact of rectal colonization by multidrug-resistant bacteria in patients with decompensated cirrhosis	Maria Hernandez-Tejero	Received

FRI-047	Metabolic syndrome delays biochemical remission in autoimmune hepatitis	Richard Parker	Received

THU-047	Recalbration of the CLIF-C ACLF score after weighting by organ and by the presence of TIPS in patients with acute-on-chronic liver failure	Enric Reverter	Received

SAT-047	Easy surveillance method without need of special equipment for muscle volume loss in patients with chronic liver disease	Atsushi Hiraoka	Received

SAT-048	Changes in the intestinal microbiome during probiotic intervention in cirrhosis	Angela Horvath	Received

FRI-048	Faecal calprotectin in PSC-IBD is a prognostic marker of cholangitis associated complications	Polychronis Pavlidis	Received

THU-048	Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury	Jacek Rozga	Received

THU-049	Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure	Sabrina Rueschenbaum	Received

SAT-049	Lactate but not hemoglobin is a predictor for mortality in patients with liver cirrhosis and upper GI bleeding	Thomas Horvatits	Received

FRI-049	Real world experience of obeticholic acid (Ocaliva) for the treatment of primary biliary cholangitis in the secondary care setting	Anthony Pratt	Received

FRI-050	Antibodies to human beta-tubulin isotype 5 in autoimmune liver disorders - re-evaluation of their specificity and clinical relevance	Beate Preuss	Received

THU-050	Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis	Jelte Schaapman	Received

SAT-050	Silymarins significantly improve long term survival in patients with liver cirrhosis regardless of MELD score	Chien-Hao Huang	Received

SAT-051	The effects of portal vein thrombosis to patients with cirrhotic variceal bleeding underwent endoscopic treatment	XIAOQUAN HUANG	Received

THU-051	Establishment of a new animal model for the acute-on-chronic liver failure	Katharina Maria Schwarzkopf	Received

FRI-051	Pregnancy outcomes in women with autoimmune hepatitis	Mussarat Rahim	Received

THU-052	Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure	Arjuna Singanayagam	Received

SAT-052	Right psoas muscle area: Prognostic factor in patients with cirrhosis Child Pugh class C included on the waiting list for liver transplantation	Speranta Iacob	Received

FRI-052	Long-term bezafibrate therapy does not prevent the progression of primary biliary cholangitis in patients with advanced disease	Anna Reig	Received

FRI-053	Overlap of primary biliary cholangitis and autoimmune hepatitis. Natural history and prognosis in a large cohort of patients from Spain	Anna Reig	Received

FRI-054	Immune-related hepatitis as an independent entity from autoimmune hepatitis: clinical, prognostic and therapeutic differences	Mar Riveiro-Barciela	Received

SAT-054	A higher prevalence of colorectal adenomatous polyps in patients with liver cirrhosis compared with non-cirrhotics	Mohamed Saleh Ismail	Received

FRI-055	Failure to normalize ALT and IgG in Autoimmune Hepatitis is associated with more advanced liver disease: Perspectives from a multi-ethnic Canadian AIH registry	Surain Roberts	Received

SAT-055	Dobutamine counteracts the decrease in cardiac output after terlipressin in patients with cirrhosis and impaired kidney function but does not improve GFR: A randomised exploratory trial	Mads Israelsen	Received

FRI-056	Obeticholic acid as adjunctive therapy in Primary Biliary Cholangitis: A review of early real-world experience	Surain Roberts	Received

SAT-056	Development of a novel prognostic model for cirrhotic patients with difficult-to-treat ascites and low MELD scores	Peter Jepsen	Received

THU-056	Artificial liver support system improves short-term survival of patients with hepatitis B virus-related acute-on-chronic liver failure: A propensity-score matched analysis	Jun Li	Received

FRI-057	A review of primary biliary cholangitis practice in Wales: Time for specialist care	Lavanya Shenbagaraj	Received

SAT-057	Proton pump inhibitors as a risk factor for hepatic encephalopathy and infections in cirrhotic patients: A clinical evidence	Mafalda João	Received

FRI-058	Randomized controlled trial to compare efficacy of albumin dialysis using MARS versus new adsorbent recirculation for pruritus treatment	Jan Stange	Received

SAT-058	In hepatic cirrhosis, the systemic levels of short chain fatty acids inversely correlate with the level of endotoxemia, and are negatively associated with an increased inflammatory response, impaired liver function and a higher HVPG	Oriol Juanola	Received

THU-058	Gene profiling of toll-like recepter signaling pathways in patients with acute-on-chronic liver failure	Ruihong Zhao	Received

FRI-059	Systematic review and meta-analysis of bezafibrate in combination with ursodeoxycholic acid in patients with treatment refractory primary biliary cirrhosis	Ted Stoklosa	Received

SAT-059	Prevalence and clinical characteristics of malnutrition in cirrhosis according to new EASL practice guidelines	Daewon Jun	Received

SAT-060	Prognostic effect of subcutaneous adipose tissue on survival outcome in patients with liver cirrhosis	Seong Hee Kang	Received

FRI-060	Effects of the ileal bile acid transport inhibitor A4250 on pruritus and serum bile acids in patients with biliary atresia: phase 2 study results	eva hortas	Received

FRI-061	Colorectal cancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: A systematic review and meta-analysis	Tom Thomas	Received

SAT-061	Performance of Baveno criteria with shear-wave elastography in patients with compensated advanced chronic liver disease	Seong Hee Kang	Received

FRI-062	Identifying research priorities in primary sclerosing cholangitis: Driving clinically meaningful change from the patients perspective	Palak Trivedi	Received

THU-062	Exploring the immune environment in chronic hepatitis C associated fibrosis by examining the portal vein	Rabab Oun Ali Anwar Ali	Received

SAT-062	Edema index measured by bioelectrical impedance analysis predicts ascites or acute kidney injury after liver resection for hepatocellular carcinoma	Soon Sun Kim	Received

FRI-063	Low-dose prednisone increases the risk of adverse events in autoimmune hepatitis patients	Floris Van Den Brand	Received

THU-063	Synergistic antifibrotic effect of rapamycin and zoledronic acid in advanced murine biliary fibrosis	Misbah Aslam	Received

SAT-063	Third-generation cephalosporins are still useful as the empirical antibiotics for spontaneous bacterial peritonitis in Korea	Sun Woong Kim	Received

SAT-064	The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis	Ji Jade King	Received

FRI-064	Systematic review and meta-analysis of risk factors for recurrent primary sclerosing cholangitis	Iris Steenstraten	Received

THU-064	Identification of new epigenetic targets in hepatic fibrosis	Marina Barcena-Varela	Received

FRI-065	The Amsterdam cholestatic complaints score is a valid patient reported outcome measure for cholestatic symptoms in PSC patients	Kim Van Munster	Received

THU-065	Metformin reverses liver fibrosis via AMPK/PGC-1a mediated mitochondrial metabolic switch	Jianye Cai	Received

SAT-065	Shear wave elastography for skeletal muscle: A novel approach to insulin resistance in cirrhosis	Kazufumi Kobayashi	Received

THU-066	Association of apri index and elastography by shear wave elastography	EIRA CERDA REYES	Received

SAT-066	Modified SAE tecnique provides a long last sustained hemodynamic response on splenic artery blood velocity in patients with cirrhosis and clinically significant portal hypertension	Sergii Kozlov	Received

FRI-066	Rituximab therapy is effective for inducing remission in IgG4-RD hepatobiliary disease: A retrospective case series	Danielle T Vannan	Received

FRI-067	Management of primary biliary cholangitis in the pre-obeticholic acid era, and the rate of non-response to ursodeoxycholic acid (UDCA), in a large real-world cohort of PBC patients in Italy: The CLEO-AIGO database	Umberto Vespasiani-Gentilucci	Received

SAT-067	Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis	Wolfgang Maximilian Kremer	Received

THU-068	Alcoholic and nonalcoholic fatty liver disease and liver-related mortality: A cohort study	Yong Kyun Cho	Received

FRI-068	Quantitative biliary tree imaging by MRI: Evaluating new technology across patient cohorts with autoimmune liver disease	gary woodward	Received

SAT-068	Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit	Alica Kubesch	Received

SAT-069	Interleukin 6: A marker for hepatic encephalopathy	Christian Labenz	Received

FRI-069	Quantitative MRCP imaging: Preliminary observations in a cohort of paediatric patients with liver and biliary diseases	gary woodward	Received

THU-069	Human adipose derived stem cells exhibit enhanced liver regeneration in liver fibrosis model by controlled releasing hepatocyte growth factor	Ja Sung Choi	Received

SAT-070	A clinical pathway to manage patients with decompensated cirrhosis: Assessing the level of compliance with evidence based guidelines	Abdulnasser Lafta	Received

THU-070	The nuclear factor TCF20 regulates the severity of liver fibrosis in mice	Bernat Cordoba-Jover	Received

FRI-070	Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country	Sun Yoo	Received

SAT-071	Insulin resistance in cirrhotic patients: results from a large prospective study	Nicolas Lanthier	Received

THU-071	Matrix modulation in chronic liver injury and resolution	Marika Crescenzi	Received

FRI-071	AMA-positives without PBC and healthy subjects have similar bile acid profiles but are different from PBC patients	Stephan Zandanell	Received

THU-072	N-ras protects against experimental liver fibrosis by maintaining hepatocyte homeostasis	Francisco Javier Cubero	Received

FRI-072	Alteration of glucocorticoid metabolism in patients with cholestasis	Gernot Zollner	Received

SAT-073	Micronutrient deficiencies in patients with decompensated cirrhosis	Gemma Llibre Nieto	Received

THU-073	The use of APRI and FIB-4 scores versus transient elastography for the assessment of liver fibrosis stage in patients with chronic hepatitis C: Is it possible to reduce the need for elastography?	Melanie Deutsch	Received

THU-074	Anti-fibrotic effect of dimethyl fumarate on rat liver fibrosis induced by thioacetamide: Role of NF-kappa B, NLRP3, Nrf2 and autophagy	Durgesh Kumar Dwivedi	Received

SAT-074	Prevalence and risk factors of colonization by multidrug resistant bacteria in cirrhotic patients admitted to the intensive care unit in a Spanish tertiary hospital	Sara Lorente	Received

THU-075	2d- shear wave elastography for the spleen stiffness evaluation: A noninvasive marker for predicting high risk varices in patients with compensated liver cirrhosis	Fofiu Renata	Received

FRI-076	On the role of inflammation in acute paracetamol injury	Saleh Alabbas	Received

SAT-076	Long term palliative abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis: a multi-centre feasibility randomised controlled trial (the REDUCe Study)	Lucia Macken	Received

THU-077	Fibro-protective molecular and cellular mechanisms emerge during resolution from thioacetamide-induced fibrosis	Francis Gratte	Received

FRI-077	Influence of drug categorization according to labelling information in the phenotypic presentation of drug-induced liver injury (DILI): An analysis in the Spanish DILI registry	Laura Sanz-Villanueva	Received

SAT-077	Intraperitoneal activation of blood coagulation via tissue factor-exposing extracellular vesicles in patients with advanced chronic liver disease	Mattias Mandorfer	Received

SAT-078	Characterizing compensated cirrhosis patients with potential etiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Findings from large Italian administrative databases	Jie Ting	Received

FRI-078	Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases	Fernando Bessone	Received

THU-078	PBI-4050 inhibits hepatic stellate cell activation, restores autophagy, and reduces CCl4-induced liver fibrosis	Brigitte Grouix	Received

THU-079	Study of anti-fibrotic activity of human umbilical-cord tissue-derived mesenchymal stromal cells during fibrogenesis or resolution in murine models of liver fibrosis	Debashis Haldar	Received

FRI-079	HLA B14:01 is associated with Trimethoprim-sulfamethoxazole induced liver injury	Naga Chalasani	Received

SAT-079	Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients	Javier Martinez	Received

FRI-080	Herbal medicines induces severe liver injury than western medications: A nationwide multicenter retrospective research	Jun Chen	Received

FRI-081	Characterisation of severe liver injury induced by immune checkpoint inhibitors	Yana Davidov	Received

THU-081	Saracatinib, a Src family kinase inhibitor, decreases liver fibrosis	Byoung Kuk Jang	Received

FRI-082	Super stealth immunoliposomes as a strategy to overcome liposome-induced liver toxicity	Sara De Martin	Received

THU-082	Thymosin beta 4 is a potential regulator of radiation-induced liver fibrosis	Jieun Kim	Received

SAT-083	Simple non-invasive surrogates of portal hypertension predict clinical decompensation in overweight/obses patientes with cACLD	Yuly Paulin Mendoza	Received

THU-083	Predicting advanced liver fibrosis using deep learning based biopsy image analysis	Sergey Klimov	Received

FRI-083	Impact of acetaminophen on acute liver failure of unknown cause	Decoster Claire	Received

THU-084	A comparative study of anti-Fibrotic therapeutics using aptamer-based quantitative proteomics in a rat model of nonalcoholic steatohepatitis cirrhosis	Smitha Krishnan	Received

FRI-084	Targeting Toll-Like Receptor 4 signalling with TAK-242: A novel therapy for acute liver failure	Cornelius Engelmann	Received

SAT-084	Validation of hand grip strength as a nutritional assessment tool for patients with advanced liver fibrosis	Topan Mirabela-Madalina	Received

FRI-085	Development and validation of a novel non-invasive model to predict drug-induced liver injury recurrence	Chun-Yan Wang	Received

SAT-085	Selective improvement by rifaximin of changes in the inmunophenotype in patients who improve minimal hepatic encephalopathy	Carmina Montoliu	Received

THU-086	Clinical study on plasma golgi protein 73 and the progression of viral hepatitis C-induced hepatic fibrosis	Liu Lingdi	Received

FRI-086	Stem cell treatment on acute liver failure model using semipermeable Poly Lactic-co-Glycolic Acid membrane pouch	Bo-Kyeong Kang	Received

SAT-086	Opioid use is common among non-surgical inpatients with cirrhosis and is associated with increased length of stay and persistent use post-discharge	Andrew Moon	Received

THU-087	A 3-dimensional dynamic model to explore the immunomodulatory properties of the extracellular matrix and their implications in liver fibrosis	Claire Mcquitty	Received

FRI-087	The good use of paracetamol: prospective assessment of the knowledge of prescribers (practitioners, residents), pharmacists, care providers (nurses, others) and students in an university medical center	Dominique larrey	Received

SAT-087	Screening endoscopy in patients with advanced chronic liver disease beyond portal hypertension: Higher prevalence of upper gastrointestinal neoplasia in comparison to a healthy screening population	Rui Morais	Received

FRI-088	The good use of non steroidal anti-inflammatory drugs (nsaids): prospective assessment of the knowledge of prescribers (practitioners, residents), care providers (nurses), pharmacists and students in an university medical center	Dominique Larrey	Received

THU-088	Serum markers of interstitial matrix formation (PRO-C3) and basement membrane remodeling (PRO-C4 and C4M) predict recurrence of fibrosis and survival in post-liver transplanted patients	Mette Juul Nielsen	Received

SAT-088	Sarcopenia and Myosteatosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis	SILVIA NARDELLI	Received

FRI-089	Genetic deletion of Keap in hepatocytes improves liver damage, but triggers hepatitis in an Nrf2-dependent manner, in experimental toxic liver injury	LAURA MORÁN	Received

SAT-089	Evaluating the impact of non-ive beta-blocker use in decompensated cirrhosis based on setting of patient care	Rooshi Nathwani	Received

THU-089	Characterization of CDAA mouse model for non-alcoholic steatohepatitis at various time-points	Larissa Pfisterer	Received

FRI-090	Enhanced ASPP2 improves liver injury by way of an inflammatory immune regulatory mechanism in acute liver failure	Feng Ren	Received

THU-090	Non-invasive fibrosis scores (APRI, FIB4 index, BARD): Useful tools for evaluating fatty liver disease	Alina Popescu	Received

SAT-090	Location of onset of acute kidney injury in cirrhosis affects survival	Janardhan Navaratnam	Received

SAT-091	The collagen hormone Endotrophin, a biomarker of type VI collagen formation - is associated with severe decompensation and predicts transplant-free survival in patients with trans-jugular intrahepatic portosystemic shunt	Mette Juul Nielsen	Received

THU-091	Acalcemic vitamin D analogues show antifibrotic effects in vitro while paricalcitol prevents progression of established fibrosis in the CCl4 mouse-model	Florian Reiter	Received

FRI-091	HGF protector effect in intrahepatic cholestasis	Elsy Soraya Salas Silva	Received

SAT-092	The efficacy and safety of rifaximin-a: a 2-year observational study of overt hepatic encephalopathy	Rosalie Oey	Received

THU-092	Role of endothelial mitophagy during endothelial dysfunction and liver fibrosis	Maria Ruart	Received

FRI-092	Metamizole as a leading cause of drug-induced liver injury	Marcial Sebode	Received

THU-093	The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of nonalcoholic steatohepatitis	Mozhdeh Sojoodi	Received

FRI-093	Low volume plasma exchange in patients with acute liver failure: A real world study	Mohammed Sheikh	Received

SAT-093	Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience	Jacqueline OLeary	Received

THU-094	Simple prediction score to predict fibrosis in type 2 diabetes mellitus patients	Ioan Sporea	Received

FRI-094	Targeting NEDDylation protects liver from acute drug-induced damage	Simón Jorge	Received

SAT-094	Effects of branched-chain amino acids on the progression of advanced liver disease: A Korean nationwide, multicenter, prospective, observational, cohort study	Jung Gil Park	Received

THU-095	Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment	Cristina Stasi	Received

FRI-095	The overweight role in the occurrence of hepatotoxic reactions during chemotherapy of chronic lymphocytic leukaemia	Igor Skrypnyk	Received

THU-096	Development and validation of true serum biomarkers of liver fibrogenesis ans fibrolysis	Rambabu Surabattula	Received

SAT-096	Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis	Michael Praktiknjo	Received

FRI-096	Technetium-99m-GSA within the first 3d after admission as an early predictor of outcome in severe acute liver injury	Yuji Suzuki	Received

THU-097	Serum infrared spectral profile is predictive of the degree of hepatic fibrosis in chronic hepatitis C patients	Gérard Thiéfin	Received

SAT-097	Non-invasive estimation of intravascular volume status in cirrhosis by dynamic size and collapsibility Indices of the inferior vena cava using bedside echocardiography	Madhumita Premkumar	Received

FRI-097	PBI-4050 treatment decreases sepsis-induced liver injury in mice	Jean-Francois Thibodeau	Received

FRI-098	Targeting cholesterol with atorvastatin protects against valproic acid-induced sensitization to acetaminophen hepatotoxicity	Sandra Torres	Received

THU-098	Changes in liver stiffness measurements following DAA treatment among HIV/HCV-coinfected individuals: Does HIV contribute to liver disease after HCV cure?	Daniela Van Santen	Received

FRI-099	PD-1 monocytes and macrophages contribute to impaired microbial clearance following acute liver failure	Evangelos Triantafyllou	Received

THU-099	Collagen is not just collagen: Differential matrix expression induced by TgF-beta and PDGFs	Ida Villesen	Received

SAT-100	Expanding the Baveno VI criteria for the screening of varices in advanced liver disease patients	Iulia Ratiu	Received

FRI-100	Protective effects of glutathione and lipoic acid against cadmium-induced oxidative stress in rats liver	Andrej Veljkovic	Received

THU-100	FGL2 regulates liverfibrosis progression and reversal by promoting profibrotic infiltrating macrophages maintenance	Xiaoyang Wan	Received

THU-101	Artery density in human liver: A valuable measure for staging of chronic liver disease	Ian Wanless	Received

SAT-101	Detrimental effect of proton pump inhibitors in cirrhosis depends on common genetic variation	Matthias Reichert	Received

FRI-101	FGL2 deficiency resists viral fulminant hepatitis through abrogating inflammatory macrophage activation	Xiaoyang Wan	Received

FRI-102	Metabolomic and inflammatory mediator based biomarkers analysis for identification of severe drug induced liver injury	Zhongyang Xie	Received

SAT-102	Cirrhotic patients with vitamin d deficiency fail to respond to oral replacement therapy	Freya Rhodes	Received

FRI-103	A sublethal dose of acetaminophen suffices to induce the unfolded protein response in hepatocytes through an IRE1alpha-JNK1-XBP1s-dependent mechanism	Hui Ye	Received

SAT-103	Bone disease does not correlate with severity of liver disease in cirrhosis	Freya Rhodes	Received

SAT-104	Factors associated with renal replacement therapy and mortality following first episode of acute knidney injury in inpatients with cirrhosis	Susana G. Rodrigues	Received

SAT-105	Rising economic burden following the diagnosis of compensated cirrhosis among hospitalized patients with Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in Spain	Nandita Kachru	Received

THU-105	Modulation of G protein alpha inhibiting activity polypeptide 2 in hepatocytes regulate liver fibrosis	Qinggong Yuan	Received

SAT-106	Prevalence and survival of fungal peritonitis in decompensated cirrhosis	Noam Roth	Received

FRI-106	Combining endozepine-4 and blood ammonia: Does it improve the diagnosis of hepatic encephalopathy in patients with liver cirrhosis?	Mohamed Abaza	Received

FRI-107	Emerging role of taurine conjugated bile acids in the gut liver axis and on hepatic bile acid receptors in chronic hepatitis C	Rabab Oun Ali Anwar Ali	Received

SAT-107	Effect of a multifactorial intervention (non-alcoholic beer, diet and exercise) on endothelial function, nutritional status and quality of life in patients with cirrhosis	Astrid Ruiz-Margain	Received

SAT-108	Sarcopenia and nutritional status predict mortality in patients with cirrhosis undergoing liver transplant assessment	John Ryan	Received

FRI-108	Gut-derived GABA is strongly linked with cognitive impairment in cirrhosis	JASMOHAN BAJAJ	Received

FRI-109	Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration	Natalia Becares	Received

SAT-109	Spontaneous bacterial peritonitis: Will the diagnostic follow-up paracentesis be essential in approaching these patients?	Ana Santos	Received

SAT-110	Impact of rifaximin monotherapy or rifamixin plus lactulose on markers of inflammation in patients with cirrhosis and a history of hepatic encephalopathy	Arun Sanyal	Received

FRI-110	A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease	Zoe Boyer-Diaz	Received

SAT-111	Procalcitonin level is a prognostic marker in patients with liver cirrhosis	Sho Sato	Received

FRI-111	Albumin modulates endosomal TLR9 signaling in human peripheral leukocytes: A mechanism for its anti-inflammatory role in ACLF	Mireia Casulleras	Received

THU-111	High efficacy and safety of the combination HCV regimen elbasvir and grazoprevir for 8 weeks in treatment-naive non-severe fibrosis HCVGT1b-infected patients: Final results of the STREAGER study	Frederic Faure	Received

THU-112	Real-world health care resource utilization and quality of life with G/P treatment: A pooled analysis from post-marketing observational studies	Hannah Welz	Received

SAT-112	Each additional infection significantly increases mortality in patients with decompensated liver cirrhosis	Marie Schultalbers	Received

FRI-112	Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis	Louise China	Received

SAT-113	Non-invasive assessment of HVPG with quantitative MRI measures of liver T1 and superior mesenteric artery velocity at 3T	Robert Scott	Received

THU-113	Comparison between safety and efficacy of two treatment regimens for pediatric patients with chronic hepatitis C virus: Sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimen	mohamed ahmed	Received

FRI-113	Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins	Sergi Guixé-Muntet	Received

SAT-114	Impact of farnesoid X receptor polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension	Georg Semmler	Received

THU-114	A comparison of currently available direct acting antiviral HCV therapy in Canada: On the path to elimination	Arshia Alimohammadi	Received

FRI-115	Toll-like receptor 4: A novel therapeutic target for the treatment of hyperammonemia	Annarein J.C. Kerbert	Received

SAT-115	Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis	Alberto Zanetto	Received

THU-115	Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection - Results from the GermanhHepatitis C-Registry (DHC-R)	Yvonne Serfert	Received

FRI-116	Capturing the complexities of the immune system in patients with advanced cirrhosis using a whole blood culture system reveals a robust inflammatory response to endotoxin stimulation	Victoria Kronsten	Received

THU-116	Effectiveness of the salvage therapy sofosbuvir-velpatasvir-voxilaprevir (SOF-VEL-VOX) in chronic hepatitis C: Clinical practice experience from the TRIO Network	NICOLE WICK	Received

SAT-116	Development and validation of a novel model for outcome in patients with cirrhosis and acute variceal bleeding	Dr Shalimar	Received

SAT-117	Enhanced liver fibrosis score is an accurate non-invasive predictor of clinically significant and high-risk portal hypertension	Benedikt Simbrunner	Received

THU-117	Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance	Silvia Barbaliscia	Received

FRI-117	The gain of function mutation of SerpinB3 (SCCA-PD) is associated with the severity of portal hypertension and complications onset in patients with advanced liver disease	Andrea Martini	Received

SAT-118	Estimating proportion of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C in clinical centres in Sofia (Bulgaria) and Lisbon (Portugal): Results from a European pilot	Marieta Simonova	Received

THU-118	Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study	Sofia Bartlett	Received

FRI-118	Decreased cognitive performance is associated with reduced resting state connectivity and gray matter atrophy in patients with minimal hepatic encephalopathy	Carmina Montoliu	Received

FRI-119	Distinct salivary microbiome profile in patients with decompensated cirrhosis	Theodora Oikonomou	Received

SAT-119	Comparison of liver frailty index at admission and 30 days after discharge from hospital in patients with advanced chronic liver disease	Lubomir Skladany	Received

THU-119	Direct-acting antiviral regimens without protease inhibitors may help maintain a healthy lipid profile after hepatitis C eradication	Javier Fuentes	Received

FRI-120	Structural liver disease rather than portal hypertension is the predominant factor for hepatic macrophage activation in patients with cirrhosis, portal vein thrombosis and idiopathic portal hypertension	Nikolaj Worm rntoft	Received

THU-120	Hepatitis C In children: Clinical profile and outcomes In the era of directly-acting antivirals in a tertiary centre in North India	Vybhav Gummadi	Received

SAT-121	Predicting sarcopenia in patients with cirrhosis based on clinical and laboratory parameters using machine learning	Guido Stirnimann	Received

THU-121	Real world outcomes from NS5a treatment failures undergoing therapy with sofosbuvir/velpatasvir/voxilaprevir and sofosbuvir/glecaprevir/pibrentasvir	Alison Boyle	Received

FRI-121	Portal hypertension in nodular regenerative hyperplasia is caused by vascular remodeling with extensive regression of portal vein branches	Christian Perez Shibayama	Received

THU-122	Sofosbuvir/velpatasvir /- ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen	Giuseppina Brancaccio	Received

SAT-122	Cirrhotic cardiomyopathy: An observational study pre-liver transplant	Mohsan Subhani	Received

THU-123	No effect of alcohol consumption or dependence on treatment outcome in chronic hepatitis C patients treated with Elbasvir/Grazoprevir in a real-world setting	Jean-Pierre Bronowicki	Received

SAT-123	Serum Mac-2 binding protein glycosylation isomer and handgrip strength correlate with serum myostatin level in chronic liver disease	Tomoyuki Suehiro	Received

FRI-123	Transcriptomic and functional analysis of Kupffer cells in patients with cirrhosis reveals a tumour associated macrophages profile and an impaired immune response that are associated with increased risk of infections	ELISA POSE	Received

FRI-124	Increased prevalence of low-frequency and rare NOD2 variants in patients with liver cirrhosis	Matthias Reichert	Received

SAT-124	Microbiological culture yield from ascitic fluid and changing antimicrobial sensitivities over time	Rachael Swann	Received

THU-124	Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)	Jose A. Carrión	Received

THU-125	High real-world effectiveness of elbasvir/grazoprevir in PWID on opioid substitution therapy with HCV genotype 1 infection: Results from the German hepatitis C registry (DHC-R)	Stefan Christensen	Received

SAT-125	Animal naming test is simple and reliable for diagnosis of minimal hepatic encephalopathy and prediction of development of overt hepatic encephalopathy in patients with cirrhosis	Sunil Taneja	Received

FRI-125	The phase angle determined by bioelectrical impedance is a predictive factor of hospitalization, falls and mortality in patients with cirrhosis	Eva Roman	Received

FRI-126	Innovative potential biomarkers in spontaneous bacterial peritonitis from ascitic fluid	Sophia Scherm	Received

THU-126	HCV treatment outcomes among current and remote injection drug users: Real- life data	Tianna Magel	Received

SAT-126	Minimal hepatic encephalopathy: Proper diagnosis for a better quality of life	Vlad Taru	Received

SAT-127	The clinical course of recurrent versus refractory ascites in outpatients with cirrhosis	Marta Tonon	Received

FRI-127	Measuring dynamics of portal pressure and vital parameters in conscious rats using real-time telemetry	Philipp Knigshofer	Received

THU-127	Clinical Practice experience with pan genotypic therapies glecaprevir-pibrentasvir and sofosbuvir-velpatasvir in the TRIO Network	NICOLE WICK	Received

SAT-128	The natural history of acute kidney disease in patients with cirrhosis	Marta Tonon	Received

FRI-128	Mesenchymal stem cells cultured in hypoxic conditions had multi-directional effects on mice with liver cirrhosis through prostaglandin E2 and miR210 production	Atsunori Tsuchiya	Received

THU-128	Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study	Roberta DAmbrosio	Received

THU-129	New antiviral therapy and the quality of life in patients with HCV infection	Claudia Monica Danilescu	Received

SAT-129	Type 2 diabetes in patients with liver cirrhosis: prevalence, associated factors and influence on survival	Maria Torner Simó	Received

FRI-129	A defect in the Nrf2/HO-1 pathway and Nox2 activation results in regulatory T cell mitochondrial dysfunction in alcohol related cirrhosis	Trishan Vaikunthanathan	Received

THU-130	Management strategies for drug drug interactions between direct oral anticoagulants and hepatitis C directly acting agents: A multi-centre review	Katherine Davidson	Received

SAT-130	Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study	Giulia Tosetti	Received

FRI-130	Changes in the extracellular matrix of the heart and the liver assessed by MRI with T1-mapping are closely linked in cirrhosis: Is inflammation the shared pathway?	Signe Wiese	Received

SAT-131	The impact of sustained virological response on the criteria used to rule out high risk esophageal varices in HCV-related compensated advanced chronic liver disease	Giulia Tosetti	Received

THU-131	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks	Elisabetta Degasperi	Received

FRI-131	Impact of HBsAg level on cellular immune responses in HBeAg negative patients with chronic hepatitis B virus infection	Elmira Aliabadi	Received

SAT-132	Incidence and prognostic factors of de novo development /worsening of esophageal varices in HCV-related compensated advanced chronic liver disease after sustained virological response achieved by direct antiviral agents	Giulia Tosetti	Received

FRI-132	In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B	Oliver E Amin	Received

THU-132	Decentralised care with generic direct antivirals is effective in the management of patients with hepatitis C in a public health care setting: The Punjab model	Radha Krishan Dhiman	Received

SAT-133	2D-Shear-Wave elastography predicts survival in advanced chronic liver disease	Jonel Trebicka	Received

THU-133	Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience	Velia Chiara Di Maio	Received

FRI-133	HCV neutralizing antibody responses in natural infections mapped by metric multi-dimensional scaling reveals new insights into HCV antigenicity and broadly neutralzing antibodies	Dorothea Bankwitz	Received

FRI-134	Comparative analysis of intrahepatic and peripheral chemokine responses in chronic hepatitis B, C and D in vivo	Jan-Hendrik Bockmann	Received

THU-134	Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment	Julia Dietz	Received

SAT-134	Hypercoagulopathy risk factors in liver cirrhosis due to non-alcoholic steatohepatitis and clinical manifestations of hypercoagulation during 5 years	Nataliya Virstyuk	Received

THU-135	Real-world HCV treatment in HCV-HIV coinfected population: Data from the TRIO network	NICOLE WICK	Received

SAT-135	Splenomegaly status does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia	Michael Vredenburg	Received

FRI-135	Toll-like receptor signalling induces changes in the Hippo signalling pathway that counter regulates innate immune responses in hepatocytes	Ruth Broering	Received

SAT-136	Hepatocellular carcinoma does not impact the efficacy of avatrombopag in increasing platelet counts and reducing platelet transfusions or rescue procedures for bleeding in chronic liver disease patients with thrombocytopenia	Michael Vredenburg	Received

THU-136	Ledipasvir/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non-cirrhotic children and adolescents	Manal Hamdy El-Sayed	Received

FRI-136	Hepatitis B core antibody (anti-HBc) mirrors activation of hepatitis B virus-specific immune responses and exhibits direct effect on hepatitis B virus control	Chengcong Chen	Received

THU-137	DAA therapy in women of child bearing age: Accidental conception during therapy and pregnancy outcome	Manal Hamdy El-Sayed	Received

FRI-137	l-carnitine impedes hepatitis B surface antigen loss through immunosuppressive effect in chronic hepatitis B virus infection	Shuqin Gu	Received

SAT-137	Adverse drug reactions in patients with cirrhosis: analysis of spontaneous reports from the Dutch Pharmacovigilance Centre Lareb	Rianne Weersink	Received

SAT-138	Cirrhotic cardiomyopathy: A 2-year longitudinal follow-up study using advanced cardiac imaging	Signe Wiese	Received

THU-138	High efficacy and improvement in CPT class with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with CPT C decompensated cirrhosis	eva hortas	Received

FRI-138	HBVcore- versus HBVpolymerase-specific CD8 T cells differ in chronically HBV-infected patients	Kathrin Heim	Received

FRI-139	Intrahepatic transcriptional profiling of chronic hepatitis B patients during interferon-alpha treatment	Minhui Dong	Received

SAT-139	Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation	Florence Wong	Received

THU-139	Real world experience of chronic hepatitis C retreatment with genotype specific regimens in non-responders to previous interferon-free therapy	Robert Flisiak	Received

FRI-140	Chemokine (C-X-C motif) ligand 13-mediated recruitment of intrahepatic chemokine (C-X-C motif) receptor 5CD8 t cells contribute to viral control in chronic hepatitis B patients and hepatitis B virus mouse model	Yongyin Li	Received

THU-140	Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy	Robert Flisiak	Received

SAT-140	The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites	Florence Wong	Received

SAT-141	The diagnosis of hepatorenal syndrome: How much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start?	Florence Wong	Received

THU-141	Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients	Martina Gambato	Received

FRI-141	Rapid decrease in titer and breath of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved sustained virological response	Isidoro Martínez	Received

THU-142	Sofosbuvir velpatasvir voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program	Christophe Hezode	Received

FRI-142	Interferon regulatory factor 5 and soluble fibrinogen-like protein 2 in hepatitis B virus related liver diseases	Xuan Hoan Nghiem	Received

SAT-142	Incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: A territory-wide cohort study	Vincent Wai-Sun Wong	Received

THU-143	High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R)	Holger Hinrichsen	Received

FRI-143	Liver-resident HBV-specific CD8 T cells are long-lived and can be replenished by allogenic responses following transplantation	Laura J Pallett	Received

FRI-144	Performance study of new geenius HCV supplemental assay	Anthony Palvadeau	Received

THU-145	High real-world effectiveness of elbasvir/grazoprevir in a HCV genotype 1 population with a migration background and predominant subtype 1b infection: Results from the German hepatitis C registry (DHC-R)	Dietrich Hppe	Received

FRI-145	Direct acting antiviral treatment decreases inhibitoryTIM-3 immune checkpoint receptor expression on NKcells in patients with chronic HCV	Gabriella Par	Received

SAT-146	Assessing liver function in patients who underwent balloon occluded retrograde transvenous obliteration	Thomas Xu	Received

THU-146	LDV/SOF/RBV is an effective first-line DAA regimen as well as re-treatment option for RF1_2k/1b patients within Georgian national hepatitis C elimination program	Marika Karchava	Received

FRI-146	Long-term nucleos(t)ide-analogue treatment in chronic hepatitis B eAg(-) together with a low level of HBsAg leads to a non-exhausted HBV-specific T CD8 response	Julia Peña Asensio	Received

FRI-147	Gradual restoration of HCV-specific CD8 T cell frequency but persistence of altered phenotype in cirrhotic HCV-infected patients after successful direct-acting antiviral therapy	Elena Perpiñán	Received

SAT-147	Interaction between renal and liver impairment on the risk of lactic acidosis in diabetic patients with chronic hepatitis B-related cirrhosis	Terry CF Yip	Received

FRI-148	Downregulation of innate and adaptive gene expression alleviated by host protein osteopontin in an immunocompetent model of hepatitis B infection	Sandra Phillips	Received

SAT-148	The role of kidney biomarkers in cirrhotic patients with acute kidney injury: interim analysis of multicenter, prospective cohort study	Jeong-Ju Yoo	Received

THU-148	Variability of ed extracellular matrix proteins concentrations in HCV infected patients treated with sofosbuvir and ledipasvir	Krzysztof Tomasiewicz	Received

FRI-149	Comprehensive transcriptome analysis of liver biopsies from chronically infected HBV patients	Ricardo Ramirez	Received

SAT-149	Optimal ion of sedative drug during endoscopy in cirrhotic patients to avoid minimal encephalopathy	Jeong-Ju Yoo	Received

FRI-150	Association of the immunodominant HLA-B35:01 restricted CD8 T cell epitope with clustered viral evolution in HBV polymerase	Elahe Salimi Alizei	Received

SAT-150	Validation of Korean stroop test in the screening of minimal hepatic encephalopathy	Eileen Yoon	Received

THU-150	Factors associated with treatment failure with SOFRBV in patients with genotype 2 chronic hepatitis C and consideration of retreatment with GLEPIB in patients not responding to SOFRBV	Atsunori Kusakabe	Received

SAT-151	What are the predictors of impairment of patient-reported outcome in non-alcoholic steatohepatitis?	Zobair Younossi	Received

THU-151	Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies	Hannah Welz	Received

FRI-151	Characterization of regulatory T cells and the role of PD-1 and TNF-alpha in spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B	Fen Liu	Received

SAT-152	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation	Giacomo Zaccherini	Received

SAT-153	A systematic review and meta-analysis of the efficacy of magnetic resonance spectroscopy in the diagnosis of hepatic encephalopathy	Georgia Zeng	Received

FRI-153	Potent hepatitis B core-specific B cell responses associate with clinical parameters in untreated and virally suppressed chronic HBV patients	Thomas Vanwolleghem	Received

THU-153	Is sofosbuvir-based regimen safe and effective in hepatitis C virus-infected patients with stage 4-5 chronic kidney disease? A systematic review and meta-analysis	Mingshu Li	Received

FRI-154	Augmentation of HBV-specific CD4 T cell responses via combined OX40 stimulation and PD-L1 blockade	Katharina Wild	Received

SAT-154	Acute hemodynamic response to I.V propranolol during hepatic hemodynamic study in 26 cirrhotic patients with portal hypertention and nonbleeding esophageal varices. Correlation with esophageal bleeding and survival	Eli Zuckerman	Received

THU-154	Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy	Seng Liem	Received

THU-155	Polymeric, metallic nanoparticles, and curcumin as inhibitors of hepatitis C virus genotype 4a replication in vitro	samah khalil	Received

THU-156	Real world outcomes for Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an uned cohort	Fiona Marra	Received

FRI-157	Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation	Leda Bassit	Received

THU-157	Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection	Marianne Martinello	Received

THU-158	High efficacy of sofosbuvir and velpatasvir regardless of patients clinical characteristics	Vitor Hugo Martins	Received

SAT-159	Genetic determinants in critical domains of NS5A are associated with genotype 1b HCV-induced hepatocellular carcinoma	Mohammad Alkhatib	Received

FRI-159	Can HBcrAg and pre-genomic HBV RNA predict the risk of ALT flares after nucleoside analogue therapy withdrawal: delineating the clinical utility of new biomarkers?	Ivana Carey	Received

THU-159	Real-world efficacy of elvasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group	Toshie Mashiba	Received

THU-160	Outcomes of the national strategy on hepatitis C treatment with direct acting antivirals in a real-life setting: Results from a national survey in Slovenia	Jerneja Videcnik Zorman	Received

SAT-160	Timing of exposure to dimethyloxalylglycine-mediated hypoxia determines opposite effects in an experimental model of hepatitis C virus infection	Matteo Nazzareno Barbaglia	Received

FRI-160	The role of soluble propragmmed cell death protein 1 on HBV relapse after cessation of entecavir therapy in HBeAg-negative non-cirrhotic patients	Chien-Hung Chen	Received

SAT-161	Prevalence of HBV and syphilis co-infection in Ulaanbaatar population, Mongolia	Delgerbat Boldbaatar	Received

THU-161	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R)	Yvonne Serfert	Received

SAT-162	Serum HBV RNA as a predictor of incomplete HBV DNA suppression following initiation of nucleoside therapy in HBV/HIV co-infected individuals	Ruth Byrne	Received

FRI-162	Prime-boost vaccination strategies using chimpanzee-adeno and MVA viral vectored vaccines encoding multiple HBV antigens (CPmutS) and class II invariant chain molecular adjuvants induces robust T-cell and anti-HBs antibody response in mice	Senthil Kumar Chinnakannan	Received

THU-162	The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets	Shahin Merat	Received

SAT-163	HBeAg-negative chronic infection: more complex and conserved quasispecies in Hepatitis B X gene	Maria Francesca Cortese	Received

FRI-163	Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study	Hannah Choi	Received

THU-163	Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis	Marcus Maximilian Mcke	Received

THU-164	High cure rates of hepatitis C in a genotype 3 predominant Pakistani community using generic direct acting antivirals	Ammara Naveed	Received

SAT-164	Characterization of HBV kinetics during infection and treatment in primary human hepatocytes	Harel Dahari	Received

FRI-164	Prognostic value of various liver scoring systems in cirrhotic chronic hepatitis B patients with and without tenofovir disoproxil fumarate treatment	Jonggi Choi	Received

THU-165	The risk of HBV reactivation among HBV/HCV co-infected patients treated with direct-acting antiviral agents: A single center experience	Young Joo Park	Received

FRI-165	No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy	Jonggi Choi	Received

FRI-166	Treatment recommendations for chronic hepatitis B and the risk of hepatocellular carcinoma	Moon Seok Choi	Received

THU-166	Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy	Luisa Pasulo	Received

SAT-166	Hepatitis C virus-based experimental models in the study of liver-driven altered glucose homeostasis	Diana Gomes	Received

THU-167	Prevalence, linkage to care and treatment of hepatitis C virus in person who inject drugs under opioid substitution therapy in a Spanish area	Ylenia Perez Castaño	Received

SAT-167	Hepatitis-E-genome sequencing via capture-probe targeting and NGS allows characterisation of viral variability	Swantje Gundlach	Received

FRI-167	Effectiveness and safety with tenofovir alafenamide (TAF) for hepatitis B in US clinical practice	NICOLE WICK	Received

FRI-168	Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling	Harel Dahari	Received

THU-168	Real-life effectivness and safety of glecaprevir/pibrentasvir in HCV infected patients with chronic kidney disease	Andrea Aglitti	Received

THU-169	Genotype 4 RAS patterns in a European hepatitis C cohort	Stephanie Popping	Received

FRI-170	Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada	Mina Farag	Received

THU-170	Real-world effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 4 infection: Results from a Veterans Affairs population	Amy Puenpatom	Received

SAT-170	A phenotypic resistance assay for clinical HCV isolates could help rationalise DAA therapy in individuals experiencing recurrent virologic failure	Christopher Jones	Received

THU-171	Effectiveness of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 infection receiving dialysis	Amy Puenpatom	Received

SAT-171	HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit	Senem Ceren Karatayli	Received

FRI-171	A phase 1 single ascending dose study of the safety, tolerability and pharmacokinetics of CRV431	Jill Greytok	Received

THU-172	Its the ribavarin, stupid: an analysis of 10,000 hepatitis C treatment monitoring encounters and the factors associated with side-effects and non-adherence	ADELAIDE MARIA RANDAZZO	Received

SAT-172	Novel mathematical modeling of HBsAg kinetics during long-term antiviral treatment: A pilot study	Hwi Young Kim	Received

FRI-172	Outcomes of response guided therapy with pegylated interferon alpha 2a in chronic hepatitis B and D	George Sebastian Gherlan	Received

FRI-173	Modeling HBV kinetics in mice treated by a novel TLR7 agonist, alone or in combination with entecavir	Antonio Gonalves	Received

SAT-173	Global patterns of HBV genotype E epidemic dispersal from Africa determined using a full-genome phylogenetic and phylogeographic approach	Evangelia-Georgia Kostaki	Received

THU-173	Sofosbuvir based anti-HCV therapy: Safe in hemodialysis	Adnan Salim	Received

THU-174	Efficacy of L-Carnitine on the ribavirin induced hemolytic anemia for patients with HCV infection	Shinya Sato	Received

FRI-174	Discovery of novel therapeutic targets for decreasing HBsAg, focusing on host proteins binding to HBV RNAs	Ryota Haba	Received

SAT-174	Formation of the occult chronic hepatitis B during antiviral therapy in patients with HIVHBVHDVHCV infection: Clinical cases	Vitalii Sukachev	Received

THU-175	Eligibility and feasibility of hepatitis C treatment in the era of direct-acting antiviral agents: Our experience in real-world practice	Monica Schiavini	Received

SAT-175	Recruitment of HBx on HBV DNA depends on FXR and is inhibited by FXR agonist	Benot Lacombe	Received

FRI-175	Frequency,severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study	Svenja Hardtke	Received

THU-176	Weight gain after interferon-free clearance of chronic hepatitis C: Results from the German hepatitis C registry (DHC-R)	Yvonne Serfert	Received

FRI-176	Orally administered TQ-A3334 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics single and multiple ascending doses in healthy Chinese subjects	Yue Hu	Received

SAT-176	The effect of HBV and HCV infection on pregnancy status	Tadeusz, Wojciech Lapinski	Received

FRI-177	Association of prophylactic anti-HBV therapy with improved long-term survival in patients with hepatocellular carcionoma undergoing transarterial therapy	Jeong Won Jang	Received

THU-177	Interim results of an ongoing project to eliminate chronic hepatitis C in people who inject drugs with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals in Vienna	Caroline Schmidbauer	Received

SAT-177	Loss of HBsAg by patients with high levels of HBV-DNA during treatment with nucleoside or nucleotide analogues	Tadeusz, Wojciech Lapinski	Received

THU-178	Drug-drug interactions in HCV therapy: Still relevant for clinical practice?	Benjamin Schulte	Received

FRI-178	The clinical significance and predictors for precipitous HBsAg decline in off entecavir therapy HBeAg negative patients	Rachel Wen-Juei Jeng	Received

THU-179	Never too old to be direct acting antiviral treated for hepatitis C virus	David Mackie	Received

SAT-179	Human liver organoids culture as a novel in vitro model of HBV infection	Chuan Kok Lim	Received

FRI-179	Antiviral therapy might not be required for chronic hepatitis B patients in the immune-tolerant phase with a significantly low incidence rate of liver-related events	Mi Young Jeon	Received

SAT-180	Hepatitis delta genotype 1 and 3 do not replicate after coinfection in the same cell in vivo	Marc Ltgehetmann	Received

FRI-180	JNJ-64530440, a novel capsid assembly modulator: single- and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers	Gail Edwards	Received

THU-180	Treatment of genotype 3 HCV infection in the large real-life Navigatore Lombardia multicentre cohort: Results from three different regimens	Alessandro Soria	Received

THU-181	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study	eva hortas	Received

SAT-181	Efficacy and safety of glecaprevir/pibrentasvir in patients with severe renal impairment in Japan: A prospective, multicenter study (KTK 49 Liver Study Group)	Masanori Atsukawa	Received

FRI-181	Efficacy and safety of switching therapy from tenofovir disoproxil fumarate to tenofovir alafenamide for hepatitis B virus infection	Shun Kaneko	Received

THU-182	The PRIORITIZE study: A pragmatic, randomized study of oral regimens for hepatitis C- transforming decision-making for patients, providers, and stakeholders	eva hortas	Received

FRI-182	Anti-viral treatment in patients with immune tolerant-phase chronic hepatitis B may be cost-effective	Hye-Lin Kim	Received

SAT-182	Full length deep sequencing of South African hepatitis B virus isolates reveals increased viral diversity and X-gene deletions in hepatocellular carcinoma patients	Anna McNaughton	Received

SAT-183	High resolution insight into hepatitis B virus infection and immunity in Africa to inform on intervention strategies	Anna Mcnaughton	Received

THU-183	Prospective multicenter study of glecaprevir plus pibrentasvir combination therapy for patients with chronic hepatitis C	Akihiro Tamori	Received

SAT-184	Approximation of the genotype distribution within global chronic hepatitis B virus infections	Thomas Michler	Received

FRI-184	Function and drug combination studies in cell culture models for AB-729, a subcutaneously administered siRNA investigational agent for chronic hepatitis B infection	Amy Lee	Received

THU-184	Correlates of unsuccessful hepatitis C virus therapy and recurrent viremia among active drug users: A mixed methods analysis	Astou Thiam	Received

SAT-185	Is the performance of ultra-sensitive HBsAg Fujirebio assay consistent across HBV genotypes (comparison between CLEIA HBsAg HQ Fujirebio and Abbott Architect assays)	Christiana Moigboi	Received

THU-185	Effectiveness and safety of DAA-based treatment of hepatitis C patients with severe and end stage chronic kidney diseases - EpiTer-2 database analysis	Krzysztof Tomasiewicz	Received

FRI-185	Virological and immunological predictors of long-term ouctomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B	I-Cheng Lee	Received

SAT-186	Pathophysiological impact of HCV on mitochondrial composition and functions	Léa Monnier	Received

THU-186	Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-August 2018	Tengiz Tsertsvadze	Received

FRI-186	Entecavir plus pegylated interferon alfa-2a and sequential HBV vaccination increases the chance of HBsAg-seroclearance: Results from a randomized controlled EVIP trial	Jeong-Hoon Lee	Received

SAT-187	characterization of hepatitis e infection in israel: identification of HEV-7 in camels and high seroprevalence in specific human populations	Orna Mor	Received

FRI-187	Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and liver-related events in patients with chronic hepatitis B: A propensity score analysis	Sung Won Lee	Received

THU-187	Objective evidence of neurocognitive impairment associated with hepatitis C virus infection and of its regression after viral clearance with direct antivirals	Gloria Vaghi	Received

SAT-188	Expansion and genetic modification of primary hepatocytes to study long-term hepatitis B virus infection	Paul Park	Received

FRI-188	Sequence analysis of baseline and on-treatment samples from HBV-infected chronic hepatitis B patients treated for 28 days with JNJ-56136379 monotherapy	Gail Edwards	Received

THU-188	Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R)	Yvonne Serfert	Received

FRI-189	HBcrAg decline in JNJ-56136379-treated chronic hepatitis B patients: Results of a phase 1 study	Gail Edwards	Received

SAT-189	GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients	Kai-Henrik Peiffer	Received

THU-189	Role of comorbidites in sofosbuvir-based treatment response: Clinical experience from an Italian real life cohort	Giulia Verzon	Received

SAT-190	Specific genetic elements in HBsAg C-terminus profoundly affect HBsAg levels in vivo, hamper HBsAg secretion in vitro and alter HBsAg structural stability in HBeAg-negative chronic HBV genotype D infection	Lorenzo Piermatteo	Received

THU-190	Characteristics associated with sustained virologic response in chronic hepatitis C patients who received an abbreviated course of direct-acting antiviral therapy	Kirsten Vest	Received

FRI-190	Incidence and predictors of flares after discontinuing nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study	Seng Liem	Received

SAT-191	Host genome integration of hepatitis B is prolific and is the primary contributor to viral HBs antigen gene expression	Ondrej Podlaha	Received

THU-191	The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK	Zoe Ward	Received

FRI-191	EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo	Kai Lin	Received

SAT-192	Targeting the HBx-DDB1-Cullin complex inhibits transcription from HBV covalently closed circular DNA in susceptible hepatoma cells	Bingqian Qu	Received

THU-192	All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100 svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china	Lai Wei	Received

FRI-192	Tenofovir disoproxil fumarate treatment in chronic hepatitis B patients with cirrhosis reduces hepatic decompensation, hepatocellular carcinoma and death	Ken Liu	Received

THU-193	4 week treatment for hepatitis C: A randomized controlled trial (4RIBC)	Lone Wulff Madsen	Received

SAT-193	Evolutionary relationship among hepatitis B virus genotype D in Latin America and Europe	João Renato Rebello Pinho	Received

FRI-193	Long-term renal and bone safety of tenofovir disoproxil fumarate in chronic hepatitis B patients with cirrhosis	Ken Liu	Received

SAT-194	The utility of monomeric HBV genomes for interrogating the HBV cccDNA minichromosome, using in vitro and in vivo models of HBV replication	Peter Revill	Received

THU-194	Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5 or 6 infection: An integrated analysis of phase 2 and 3 studies	Salil Sharma	Received

FRI-194	The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro	Stephen Locarnini	Received

SAT-195	The novel HBx mutation F30V correlates with HCC in vivo, hampers HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro	Romina Salpini	Received

FRI-195	Long-term effect of nucleos(t)ide analogs on hepatitis B surface antigen in chronic hepatitis B patients	Kenichi Morikawa	Received

THU-195	An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resitance-associated substitution	Ming-Lung Yu	Received

SAT-196	The integrated use of highly sensitive HBV markers can predict HBV reactivation in HBsAg-negative/Anti-HBc positive patients from oncohematological setting	Romina Salpini	Received

THU-196	Efficacy of 8 versus 12-weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-weeks regimen in real world setting	Dorota Zarebska-Michaluk	Received

FRI-196	The development of HCC in chronic hepatitis B patients with nucleos(t)ide analogs: Focus on hepatitis B surface antigen and core-related antigen	Itaru Ozeki	Received

SAT-197	Quality of life measurement using wrist actigraphy in HCV genotype 1 infected, treatment nave patients suffering from fatigue and receiving ombitasvir, paritaprevir, and ritonavir tablets and dasabuvir tablets (Viekirax/Exviera; 3D regimen)	David Semela	Received

THU-197	Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis	Dorota Zarebska-Michaluk	Received

FRI-197	Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients	George Papatheodoridis	Received

SAT-198	Full-length 5RACE analysis discriminates all major intracellular and extracellular viral RNAs during the course of infection	Bernd Stadelmayer	Received

FRI-198	A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults	Gail Edwards	Received

THU-198	Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies	Hannah Welz	Received

FRI-199	First in Human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis	Daniela Paulsen	Received

THU-199	Awake the dormants: Barriers to access to care and cure in patients with chronic HCV infection	Eli Zuckerman	Received

THU-200	The Real-Eorld Israeli experience of treating mild and severe chronic hepatitis C patients with elbasvir/grazoprevir: A large multi-center cohort study	Eli Zuckerman	Received

FRI-200	Spend less get more;cost effectiveness of various models of care in hepatitis C treatment	JEYAMANI RAMACHANDRAN	Received

FRI-201	Hepatitis B virus vaccine immunogenicity in anti-HBC immunocompromised patients with low anti-HBS levels: Preliminary results of the Hepbare study	Mar Riveiro-Barciela	Received

SAT-201	Alternation of lipid metabolism and dysfunction of mitochondria might contribute to HCC development in the absence of overt necroinflammation	Jaw-Ching Wu	Received

FRI-202	Outcomes of hepatitis B patients transplanted without hepatitis B immunoglobulin	Sheetal Shah	Received

SAT-202	Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes in vitro	Zhenfeng Zhang	Received

THU-203	Hepatitis D infection and risk of hepatocellular carcinoma: A systematic review and meta-analysis of observational studies	Dulce Alfaiate	Received

FRI-203	Inhibition of hepatitis B virus replication by FAM176A via activation of PI3K-AKT-mTOR signaling pathway	Jie Yu	Received

SAT-204	Hepatitis E virus antigen in urine as a useful diagnostic method for monitoring infection and detection of recent infection	Patrick Behrendt	Received

THU-204	Analysis of interleukin 28B rs12979860 polymorphism relationship with spontaneous clearance of hepatitis D virus infection in Mongolian population	Zaya Batsuuri	Received

FRI-204	ASPP2: A potential strategy to inhibit HBV replication through reducing hepatocytes autophagy	Ying Shi	Received

THU-205	Evaluation of HBV outcomes after treatment discontinuation from 4 phase 3 studies	eva hortas	Received

FRI-205	Entecavir improves liver function and fibrosis in hepatitis B virus-associated cirrhosis: A 6 years-multicenter study	Seung Kak Shin	Received

SAT-205	Associated risk factors for hepatitis E seroprevalence among liver transplant recipients	Petra Dinjar Kujundi&263;	Received

THU-206	HBV DNA relapse after stopping nucleoside analogue therapy in patients with HBsAg loss: Detectable pre-genomic HBV RNA is a better predictor of relapse than ultra-sensitive HBsAg - implications for HBV cure	Ivana Carey	Received

FRI-206	Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos(t)ide analogues	Milan Sonneveld	Received

SAT-206	The impact of hepatitis E virus infection on the Scottish solid organ transplant population	Mhairi Donnelly	Received

FRI-207	Subgroup analysis of patients undergoing switch of nucleos(t)ide regimen for HBV treatment during the prospective BONIKA trial	Kathrin Sprinzl	Received

THU-207	A retrospective review of the incidence of hepatocellular carcinoma in patients with chronic hepatitis B attending the regional hepatitis clinic in Northern Ireland	Geraldine Carroll	Received

SAT-208	Zinc/Ribavirin: A possible treatment option in chronically HEV genotype 3 infected patients without SVR under ribavirin monotherapy	Thomas Horvatits	Received

FRI-208	Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos(t)id treatment in chronic hepatitis B: Results from the PADD-ON trial	Martin Sprinzl	Received

THU-208	Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA	Gian Paolo Caviglia	Received

SAT-209	Role of estrogen and its receptors in HEV associated feto-maternal outcomes	Premashis Kar	Received

FRI-209	Exploring TH1/TH2 adjuvants to improve the efficacy of the therapeutic vaccination against chronic hepatitis B	Jinpeng Su	Received

THU-209	Dynamics of a transient elastography-based risk prediction model for hepatocellular carcinoma treated with antiviral therapy in chronic hepatitis B: A multi-center retrospective cohort study from the Korean Transient Elastography Study Group	Hye Yeon Chon	Received

SAT-210	Circulation of hepatitis a genotypes in Israel 2017-2018: Environmental surveillance supports clinical findings	Orna Mor	Received

FRI-210	Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study	Andrew Vaillant	Received

FRI-211	Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection	Andrew Vaillant	Received

SAT-211	HEV infection in Italy: Beyond the hepatic disease	Giovanna Picchi	Received

THU-211	Evaluation of point shearwave elastography using acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in HBeAg-negative chronic HBV infection: A prospective longitudinal study	Christiana Graf	Received

FRI-212	HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos(t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B	eva hortas	Received

SAT-212	Treatment with mTOR inhibitors is an independent risk factor for chronic hepatitis E in transplant patients with increased transaminases levels	Mar Riveiro-Barciela	Received

THU-212	Reactivation of occult HBV infection in HIV treated for HCV: A retrospective study	Bianca Granozzi	Received

FRI-213	HBV RNA at 6 months predicts HBeAg loss in nucleos(t)ide analogue treated HBeAg positive patients: Demonstration of clinical utility?	Bo Wang	Received

THU-213	Distinct features of hepatitis delta in a Mediterranean setting	Helena Hernàndez-Èvole	Received

SAT-213	Hepatitis E virus prevalence in Flemish blood donors	Ann-Sofie Vercouter	Received

SAT-214	Incidence, predictors and prognosis of liver failure in patients with hepatitis E as an acute insult	Yijin Wang	Received

FRI-214	Novel hepatitis B virus X gene mutants emerge during antiviral therapy to increase covalently closed circular DNA accumulation conferring pseudo-drug-resistance and increaing hepatocellular carcinoma risk	Chau-Ting Yeh	Received

THU-214	Annual average of integral FIB-4 index and HBV core-related antigen as an appropriate indicators for starting nucleoside analogues at an optimum timing	Shuhei Hige	Received

SAT-215	Cryoglobulinemia in asymptomatic, symptomatic acute and chronical HEV infections	Thomas Horvatits	Received

THU-215	Association between core mutations and annual decline rate of HBVDNA and HBsAg in chronic hepatitis B patients treated with nucleoside analogue	Takashi Honda	Received

FRI-215	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: 144 weeks results of phase 3 trial	Hyung Joon Yim	Received

THU-216	Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough	Qi Huang	Received

FRI-217	Safety, antiviral activity, and pharmacokinetics of a novel hepatitis B virus capsid assembly modulator, JNJ-56136379, in Asian and non-Asian patients with chronic hepatitis B	Gail Edwards	Received

THU-217	Low risk of HBV reactivation in a large European cohort of HBV/HCV coinfected patients treated with DAA	Jerzy Jaroszewicz	Received

SAT-217	Effectiveness and safety of sofosbuvir-based regimens in treatment of chronic HCV patients aged 60 years and older, egyptian single center experience	Shereen Abdel Alem	Received

SAT-218	Impact of sofosbuvir-based therapy on renal functions indices in chronic hepatitis c patients who achieved sustained virological response	Reham Abdelmoniem	Received

FRI-218	Dynamic changes of serum hbv pgrna levels in patients with chronic hepatitis B treated with entecavir or peg-interferon	XIAOQI YU	Received

THU-219	Long-term outcome in Caucasian patients with hepatitis B e antigen-negative chronic infection: An observational cohort study	zgr Koc	Received

FRI-219	RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients	mingfen zhu	Received

SAT-219	Effect of treatment of hepatitis C by directly acting antivirals on chronic hepatitis C and B co-infected patients	Ayman Sadek	Received

SAT-220	Higher frequency of occult HCV infection in HIV/HCV coinfected patients with advanced liver disease: Post DAAs treatment observation	Sabrina Bagaglio	Received

SAT-221	Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection	Margaret Bassendine	Received

THU-222	The application of novel HBV pgRNA assay to predict HBeAg clearance on long-term nucleos(t)ide analogues	Daryl Lau	Received

FRI-222	Redundancy of elastography in mono-infected HCV individuals less than 30 years old - Development of Dillons Rule	Paul Brennan	Received

SAT-222	Improvement in liver fibrosis among patients with hepatitis C who achieved sustained viral response after direct acting antivirals treatment, in country of Georgia	George Kamkamidze	Received

FRI-223	Contribution of HBV and HCV infection in mortality of B-NHL subjects	Myagmarjav Budeebazar	Received

SAT-223	AA genotype of the deSNP rs6726639 of gene MERTK (MER Tyrosine Kinase) is associated with development of hepatocellular carcinoma after hepatitis C virus clearance	Vincenza Calvaruso	Received

FRI-224	Reaching out to the undiagnosed people with hepatitis C infection in Belgium: A pilot study	Dana Busschots	Received

SAT-224	Design and validation of a risk prediction model for hepatocellular carcinoma development after sustained virological response in chronic hepatitis C patients	Ho Soo Chun	Received

FRI-225	Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection	Joaquin Cabezas	Received

SAT-225	The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: The role of portal hypertension	Elton Dajti	Received

THU-225	Risk prediction model for hepatocellular carcinoma after hepatitis b e antigen seroclearance in patients treated with entecavir or tenofovir	Tae Seop Lim	Received

FRI-226	Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients	Harel Dahari	Received

THU-226	Concomitant diabetes mellitus increases risk of liver fibrosis in treatment-naive chronic hepatitis B with low viral loads: Results from a matched case-control study	Hei Chun Justin Ma	Received

SAT-226	beneficial effects of DAAs on right cardiac function in hcv patients with low-mild liver fibrosis	Andrea Dalbeni	Received

SAT-227	Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients	Elisabetta Degasperi	Received

FRI-227	Interleukin-6 -174G/C genotype and interleukin-10 ATA haplotype are associated with clinical comorbidities in chronic hepatitis C patients	Luciana Diniz Silva	Received

THU-227	NTCP S267F variant associates with decreased susceptibility to HBV infection and decelerated progression of related liver diseases	Thanh Binh Mai	Received

THU-228	HBV RNA can influence HBV viral load results depending on the test used	Ed G. Marins	Received

FRI-228	Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention) study	Joseph Doyle	Received

SAT-228	Sustained virologic response induced by direct-acting antivirals suppresses skeletal muscle loss in patients with type C liver disease	Kei Endo	Received

FRI-229	Reflex testing in patients with chronic hepatitis C in Spain improves healthcare outcomes and is cost effective	Federico Garcia Garcia	Received

THU-229	Increased gaps in hepatitis B pregnancy care identified among low-risk populations	Rena Mei	Received

SAT-229	Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals	Maria Sanchez-Azofra	Received

THU-230	HBV and HDV confection trends in HIV patients in Vienna	Caroline Schmidbauer	Received

SAT-230	HCV re-infection among HIV-infected MSM in New York City	Daniel Fierer	Received

FRI-231	Hostel-based models can improve the engagement of homeless individuals with liver services: VALID (vulnerable adults liver disease) study	Ahmed Hashim	Received

SAT-231	Impact of the HCV cure with DAAs in the use of concomitant medication and the serum lipid profile: Follow-up data one year after the SVR12	Elena González-Colominas	Received

THU-231	Risk of hepatocellular carcinoma in patients with immune-tolerant chronic hepatitis B	Gyeol Seong	Received

THU-232	Hepatitis B vaccination is effective among HIV-infected adults in Uganda	Emmanuel Seremba	Received

SAT-232	Reinfection following successful HCV DAA therapy among people with recent injecting drug use	Jason Grebely	Received

FRI-232	An outpatient endoscopy-based patient navigator model improves hepatitis C virus screening among high risk patients: A 3-year prospective observational study among a safety-net health system	Grishma Hirode	Received

SAT-233	Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression	Behzad Hajarizadeh	Received

FRI-233	The impact of community-based rapid point-of-care testing on enhancing uptake of hepatitis C treatment for people who inject drugs in needle and syringe services	Jessica Howell	Received

SAT-234	Risk of hepatocellular carcinoma and efficacy of direct-acting antivirals in patients with concurrent hepatitis C virus	Elizabeth Harrod	Received

THU-234	High body-mass index is associated with increased risk of alanine aminotransferase elevation and hepatocellular carcinoma in chronic hepatitis B patients with sustained viral control	Chengcong Chen	Received

FRI-234	Viral interference between dengue virus and hepatitis C virus infections	Jee-Fu Huang	Received

SAT-235	Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia	Samira Hosseini Hooshyar	Received

THU-235	Hepatitis B virus testing and cascade of care in a tertiary referral centre, Maastricht The Netherlands	Eva Van Oorschot	Received

FRI-235	Hepatitis C virus risk factors and test uptake in an English prison	Kathryn Jack	Received

THU-236	Integration of HBV DNA near cancer-related genes in HBsAg-negative hepatocellular carcinoma patients	Danny Wong	Received

FRI-236	Hepatitis C virus related liver fibrosis in people who inject drugs at the Stockholm Needle Exchange evaluated with liver elasticy	Martin Kberg	Received

SAT-236	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals	Chung-Feng Huang	Received

FRI-237	Triple E (engagement, education and eradication) for patients chronically infected with hepatitis C: Results of a self-sustaining, comprehensive education, screening and treatment program for patients in substance abuse treatment facilities	Jane Ranagan	Received

THU-237	Increasing prevalence of indications to choose bone/renal-friendly antiviral drug: A territory-wide study of 135,414 patients from 2000 to 2017	Grace Wong	Received

SAT-237	Histological improvement of hepatitis C virus patients after achieving sustained virological response with direct-acting antivirals	Rui Huang	Received

SAT-238	The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort	Naveed Janjua	Received

THU-238	Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection	Robert Wong	Received

SAT-239	Real life data on elbasvir/grazoprevir efficacy, safety and drug-drug interaction profile in patients with chronic hepatitis C viral infection: A prospective analysis in the PITER cohort	Loreta Kondili	Received

FRI-239	SAMBA II HCV: A new point of care molecular assay for HCV diagnostics and DAA monitoring	Sonny Michael Assennato	Received

THU-239	Improving patient knowledge about hepatitis B virus leads to improvements in HBV disease monitoring	Robert Wong	Received

SAT-240	Metabolic liver function improves 12 weeks after successful sofosbuvir-based direct-acting antiviral therapy in patients with chronic hepatitis C and advanced liver disease	Tea Lund Laursen	Received

FRI-240	Comparison of Abbott RealTime HCV genotype II, Abbott HCV genotype plus RUO with Roche Cobas HCV genotyping assays for hepatitis C virus genotyping	Chen-Hua Liu	Received

SAT-241	The dynamics of two plasma markers of type III collagen formation and degradation in the course of chronic hepatitis C viral clearance with direct-acting antiviral therapy	Tea Lund Laursen	Received

FRI-241	Barriers to HCV elimination among drug users: HepCare-Spain	Juan Macías	Received

THU-241	Influence of HBV genotype on the risk of hepatocellular carcinoma: mediating roles of different phase of viral infection and epigenetic modifications	Wan-Jung Wu	Received

SAT-242	Liver stiffness measurement is not a predictive factor of HCC in HCV patients with severe fibrosis who achieved SVR by DAA	Aline Le Cleach	Received

FRI-242	Absence of hepatitis C infection despite high-risk sexual behavior in a cohort of men who have sex with men screened in the community: preliminary results of SEXCHECK study	Pietro Malosso	Received

THU-242	Clinical non-invasive markers for hepatic inflammation and fibrosis assessment in chronic hepatitis B with normal alanine aminotransferase	Zhao Wu	Received

THU-243	Occult hepatitis B virus infection after haploidentical haematopoietic stem cell transplantation patients: incidence and characterization of HBV pres/s gene mutations	haiying zhang	Received

FRI-243	Utility of simple serum based tests to exclude cirrhosis prior to HCV treatment in non-hospital based settings	Jonathan Mitchell	Received

SAT-243	Ledipasvir/sofosbuvir is highly effective and safe in patients with chronic hepatitis B virus and hepatitis C virus coinfection: Final study results	eva hortas	Received

FRI-244	Platelet-derived growth factor alpha might mediate hepatic fibrosis by enhancing insulin resistance in patients with hepatitis C	Anna Mrzljak	Received

THU-244	Virological and clinical characteristics of chronic hepatitis delta patients of Mongolia	Delgersaikhan Zulkhuu	Received

SAT-244	Mixed cryoglobulinemia patients with persisting symptoms after SVR are characterized by B-cell clonality markers	Serena Lorini	Received

FRI-245	Improvement in cognitive impairment following 12 weeks of aerobic exercise in individuals with non-cirrhotic, chronic hepatitis C	Philip OGorman	Received

SAT-245	Prospective evaluation of the impact of hepatitis C cure on sexual dysfunction	Zoe Mariño	Received

SAT-246	Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: Results from a multicenter study	Chiara Masetti	Received

FRI-246	Elimination of HCV in a Large Urban Health System in the United States: A Big-data Approach	Ponni Perumalswami	Received

FRI-247	Influence of HCV coinfection and HCV treatment on risk of diabetes mellitus in HIV infected persons	Lars Peters	Received

SAT-247	The evaluation of the inhibitory effect of oral anti-hepatitis C virus agents on carcinogenesis	Seiichi Mawatari	Received

FRI-248	Cost-effectiveness of elbasvir/grazoprevir (EBR/GZR) for treatment-naive (TN) patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection in Russia	Shelby Corman	Received

SAT-248	Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years ?	Lucy Meunier	Received

SAT-249	Increased cardiovascular risk associated with chronic hepatitis C infection still remains at SVR24	Ann Monaghan	Received

FRI-249	HCV in french prisoner, the study 2017: Fewer patients but more treatment than in 2015	André-Jean Remy	Received

SAT-250	Effects of sustained virological response on the endothelial dysfunction and the cardiovascular risk in hepatitis C after direct antiviral angets treatment: HEPCAR study	Rocío Muñoz-Hernández	Received

FRI-250	Test to cure: Increase outreach linkage to care by use of real time HCV viral load	André-Jean Remy	Received

SAT-251	The association of serum IFN-?3 levels with liver fibrosis and hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents	Miyako Murakawa	Received

FRI-251	Impact of hepatitis C treatment on patterns of drug use and subsequent treatment outcomes: High SVR rates despite increasing intravenous drug use in the post treatment period	Trina Ritchie	Received

THU-251	Metabolic risk factors for advanced liver disease among alcohol risk users in the general population	Fredrik berg	Received

FRI-252	Comparing the efficacy of hepatitis C diagnostic pathways: Standard testing vs. targeted testing	Emma Robinson	Received

THU-252	Nursing staff volume is the most significant predictor of improved in-hospital mortality among alcoholic hepatitis patients admitted with ascites or hepatic encephalopathy: US nationwide population-based study	Hassan Azhari	Received

SAT-252	Long-term effect of direct-acting antivirals therapy in patients with hepatitis C-related decompensated cirrhosis: Russian single academic center experience	Ekaterina Nabatchikova	Received

SAT-253	Impact of HCV clearance on HCC development and patient survival: Propensity score-matched analysis of an ongoing database of 2173 CHC patients	Mina Nakagawa	Received

THU-253	Equal efficacy of gastric and jejunal tube feeding in liver cirrhosis and/or alcoholic hepatitis: A randomised controlled trial	Palle Bager	Received

FRI-253	Changing epidemiology of hepatitis C: A Hospital-level study	Joana Roseira	Received

THU-254	Cumulative effects of WESTERN DIET and ALCOHOL abuse: A novel MODEL of ASH/NASH-derived liver injury	Raquel Benedé	Received

FRI-254	The impact of virally induced hepatic inflammation and low to moderate alcohol consumption on liver transient elastography (Fibroscan) in patients with chronic hepatitis C virus infection treated with direct-acting antivirals	Christoffer Ruus	Received

SAT-254	Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter cohort study	Eiichi Ogawa	Received

FRI-255	Dynamics of HCV epidemiology among HIV patients in Vienna	Caroline Schmidbauer	Received

SAT-255	Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir dasabuvir /- ribavirin in the TOPAZ-I and TOPAZ-II trials	Salil Sharma	Received

THU-255	Long term outcomes of alcoholic patients without clinical evidence of liver disease: A 15 years follow-up study	Sonia Bernardo	Received

SAT-256	Influence of metabolic syndrome on fibrosis regression regulated by LOXL-2 after SVR	ANGELA PUENTE	Received

THU-256	Alpha-1 antitrypsin ameliorates experimental alcoholic liver disease and predicts patient outcome	Grander Christoph	Received

FRI-256	Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage	Giordano Sigon	Received

SAT-257	Incidence and predictors of liver outcomes in chronic hepatitis C patients: Comparison of an American and a Chinese cohort	Huiying Rao	Received

THU-257	Fungal dysbiosis in alcoholic patients is associated with the severity of the liver injury	eva hortas	Received

FRI-257	Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals	David Smookler	Received

SAT-258	Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients	Federico Ravaioli	Received

FRI-258	Sustained virologic response among non-cirrhotic persons who inject drugs: Results from the CanHepC retrospective hepatitis C registry	Alyssa Margeson	Received

THU-258	Comparison of a fast corticosteroid tapering with the standard corticosteroid schedule in severe alcoholic hepatitis	Berta Cuyas	Received

FRI-259	Characteristics and sustained virologic response of persons reporting illicit substance use in the past 6 months: Results from the CANUHC prospective patient registry	Alyssa Margeson	Received

SAT-259	Achieving accelerated elimination of hepatitis C virus infection by 2025: A case study in France	Yuri Sanchez	Received

THU-259	The gene signature-MELD score and alcohol consumption determine long-term prognosis of patients with severe alcoholic hepatitis	Pierre Deltenre	Received

SAT-260	Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets	Yuri Sanchez Gonzalez	Received

FRI-260	Improving hepatitis C care cascade through electronic health engagement	Zohha Tariq Alam	Received

THU-260	Alcoholic cirrhosis is associated with higher in-patient mortality compared to non-alcoholic cirrhosis	Xiaowen Fan	Received

THU-261	Validation of the pre-treatment neutrophil-to-lymphocyte ratio to predict response to corticosteroids in severe alcoholic hepatitis	Ewan Forrest	Received

SAT-261	Elevated HCV reinfection rates after cure on spontaneous clearance among HIV-infected and uninfected men who have sex with men	Carmine Rossi	Received

FRI-261	Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: Final results of a Swiss prospective study	Aicha Djebali-Trabelsi	Received

SAT-262	Long-term liver function outcome and related risk factors in HCV cirrhotic patients treated with direct-acting antiviral therapy: Results from the Navigatore platform in Veneto-Italy	Francesco Paolo Russo	Received

FRI-262	Genetic variants in the promotor region of the macrophage migration inhibitory factor are associated with severity of HCV-induced liver fibrosis	Theresa Wirtz	Received

THU-262	A modified Glasgow alcoholic hepatitis score incorporating the neutrophil-to-lymphocyte ratio is superior to other baseline scores of prognosis in alcoholic hepatitis	Ewan Forrest	Received

FRI-263	The VirAEmiC project: Opt out hepatitis B and C testing of 38704 patients in an urban emergency department	Terence Wong	Received

THU-263	The demonstration of antibodies to histone 2B of the IgA-type helps to differentiate between alcoholic liver disease and non-alcoholic fatty liver disorder	Amelie Frank	Received

SAT-263	Immediate versus delayed hepatitis C treatment is cost-saving in the United Kingdom: A pan-genotypic cost-effectiveness analysis	Yuri Sanchez Gonzalez	Received

FRI-264	Silencing clusterin supress the progression of hepatitis C virus-related HCC by regulating autophagy and attenuating HCC cell properties	Xiaoxiao Zhang	Received

SAT-264	Prediction of hepatocellular carcinoma development using liver stiffness after sustained virological responses by magnetic resonance elastography in patients with chronic hepatitis C	Nobuharu Tamaki	Received

FRI-265	Twelve weeks of effective resistance training did not change the gut microbiota in patients with cirrhosis	Luise Aamann	Received

THU-265	In severe alcoholic hepatitis, serum transferrin indicates impaired HNF4a signaling and predicts mortality independently of disease severity	Karim Hamesch	Received

SAT-265	Anti-VHC therapy does not increase de risk of developing splanchnic vein thrombosis in patients with cirrhosis	Fanny Turon	Received

SAT-266	High rates of early HCV reinfections after DAA therapy in active intravenous drug users attended at mobile harm reduction units	Jorge Valencia	Received

SAT-267	Occult hepatitis C in immunocompetent patients who have achieved sustained viral response is associated with persistent histological abnormality	Yijin Wang	Received

FRI-267	Serial measurement of serum dextran absorption by novel competition ELISA demonstrates larazotide acetate significantly improves leaky gut in a Western diet murine model of metabolic liver disease	Rebecca Caffrey	Received

THU-267	the increasing burden of alcohol related liver disease: A single tertiary centre experience	Arif Hussenbux	Received

SAT-268	Noninvasive prediction of gastroesophageal varies by serum wisteria floribunda agglutinin positive Mac-2 binding protein and FIB-4 index in chronic hepatitis C	Keiya Watakabe	Received

THU-268	Human microfibrillar-associated protein 4 expressed in the liver and serum in alcoholic liver disease predicts liver fibrosis severity with accuracy similar to transient elastography and enhanced liver fibrosis test	Ditlev Rasmussen	Received

FRI-268	Microbiota signature differs significantly between NAFLD and healthy controls but not between NAFL and NASH	Mnevver Demir	Received

FRI-269	Regulation of lymphangiogenesis by Paneth cells in normal physiology and experimental portal hypertension	MOHSIN HASSAN	Received

THU-269	Abnormal lipoproteins in alcoholic hepatitis cause hepatocellular injury via inflammasome activation	Maria Perez-Matos	Received

SAT-269	The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who dont achieve sustained virologic response	Zobair Younossi	Received

FRI-270	Association between gut microbiota and hepatocellular carcinoma in patients with chronic liver disease	Takashi Honda	Received

THU-270	Severe alcoholic hepatitis has no influence on prognosis of variceal bleeding in patients with alcoholic cirrhosis	Fischer Petra	Received

THU-271	Metabolic syndrome increases the risk of hepatic fibrosis in subjects with increased alcohol consumption: Results from a population-based cohort	ELISA POSE	Received

SAT-271	Genetic risk factors for advanced alcoholic and non-alcoholic liver disease in the general population	Fredrik berg	Received

FRI-271	Rifaximin alleviates endotoxemia with improved intestinal hyperpermeability with partially modified fecal microbiota in cirrhotic patients	Kosuke Kaji	Received

FRI-272	Identification of novel glycans that target gut microbiota-associated ammonia production	Amy Doherty	Received

THU-272	A study investigating the effect of extracorporeal cellular therapy with C3A cells on the survival of alcoholic hepatitis designed along the guidelines of the NIAAA	Jan Stange	Received

SAT-272	A simple algorithm based on electronic medical records to identify NAFLD with advanced fibrosis in patients with Type 2 diabetes	Naim Alkhouri	Received

THU-273	Role of PNPLA3 rs738409 and MBOAT7 rs626283 during alcohol detoxification: Indication of different mechanisms for fibrosis development	Vanessa Rausch	Received

FRI-273	Intestinal microbiota signature related to hbeag seroconversion after oral antiviral therapy	Jin-Shui Pan	Received

FRI-274	Exercise modulates gut microbiota and intestinal barrier functionality counteracting early obesity and NAFLD in an in vivo model	David Porras	Received

SAT-274	Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver in children	Daniel Halliday	Received

THU-275	Blood transcript modules differentiate steroid responders from non-responders at baseline in severe alcoholic hepatitis	Shvetank Sharma	Received

SAT-275	Interleukin-32 as a novel NAFLD biomarker in PNPLA3 I148M variant carriers	Guido Alessandro Baselli	Received

FRI-275	Fecal microbiota profiles as a diagnosis marker in PSC and PSC-IBD patients compare to healthy controls	Michal Safran	Received

SAT-276	Point shear wave elastography by ElastPQ accurately stages hepatic fibrosis in patients with NAFLD: A prospective, multicentric study	David Bauer	Received

THU-276	Women, Native Americans, and Asians experience the greatest increase in alcoholic hepatitis hospitalizations: An analysis of the 2008-2014 U.S. nationwide inpatient sample	Farah Shirazi	Received

FRI-276	Effect of korean red ginseng on non-alcohlic steatohepatitis: Randomized controlled trial	Ki Tae Suk	Received

THU-277	Significant differences in alcoholic hepatitis related mortality in the United States by sex, race/ethnicity, and insurance: An analysis of the 2008-2014 nationwide inpatient sample	Farah Shirazi	Received

SAT-277	Screening diabetic patients at risk for complications of non-alcoholic fatty liver disease: Prospective evaluation of national and international guideline recommendations	Valentin Blank	Received

FRI-277	Effect of probiotics in the treatment of NASH: A randomized clinical trial	Gabriela Zanatta Port	Received

FRI-278	RIP3-dependent signalling exerts divergent effects on liver steatosis and carcinogenesis in experimental non-alcholic fatty liver disease	Marta B. Afonso	Received

SAT-278	Integrated analysis of dna methylation and mRNA expression to identify mechanisms of non-alcoholic steatohepatitis	Noemí Cabré	Received

SAT-279	Comparison of different and new types of non-invasive fibrosis tests in NAFLD	Paul Cales	Received

FRI-279	Stat2 is a pathogenic factor in human non-alcoholic steatohepatitis and mouse models of liver injury and mediates fatty acid-induced Inflammasome activation in hepatocytes	Wenhao Li	Received

FRI-280	Common dietary component, wheat amylase trypsin inhibitors, driver of chronic liver disease in pre-clinical models of NASH and liver fibrosis	Muhammad Khan	Received

SAT-280	Comparison of CAP, MRI-PDFF, Steatotest, FLI and HSI performances for diagnosing NAFLD and NASH in morbidly obese patients undergoing bariatric surgery	Laurent Castera	Received

THU-280	Quantitative fibrosis assessment independently predicts outcome in alcoholic liver disease	Rudolf Stauber	Received

SAT-281	Protease activity sensors for non-invasive monitoring of NASH	Sophie Cazanave	Received

FRI-281	IL-4 receptor alpha knock-out mice are protected against fibrotic NASH in a representative mouse model of non-alcoholic steatohepatitis	Muhammad Khan	Received

THU-281	Single nucleotide polymorphisms associated with no interferon lambda 4 production are associated with reduced mortality in alcoholic hepatitis	Sidsel Sty	Received

SAT-282	Decrease in HbA1c accounts for the rapid decline in the measurement of liver stiffness by transient elastography in diabetic patients	Tugba Celebi	Received

THU-282	Augument of liver regeneration protects against ethanol-induced acute liver injury by promoting autophagy	YUAN Wu	Received

FRI-283	Impact on NAFLD of long-term weight loss after bariatric surgery	Chiara Barbieri	Received

SAT-283	Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976	Michael Charlton	Received

THU-283	FGF15 deficiency aggregates experimental alcoholic steatohepatitis in mice: A critical role for lipocalin 2 signaling	Min You	Received

THU-284	Hepatocyte-specific deletion of splicing factor SRSF3 exacerbates experimental alcoholic steatohepatitis in mice	Min You	Received

FRI-284	A combination of fenofibrate with a liver-targeted acetyl-CoA carboxylase inhibitor enhances efficacy while reversing plasma triglyceride increases in a murine model of NASH	Eva Hortas	Received

SAT-284	Diagnostic performance of transient elastography on liver fibrosis of patients with non-alcoholic fat hepatitis	Chun-Yan Wang	Received

SAT-285	Fibroscan-based score for detection of active nash and significant fibrosis is better than fib-4 in 361 chronic hepatitis B patients with non-alcoholic fatty liver disease	Xiaoling Chi	Received

THU-285	Loss of X-Box Protein-1 in intestinal epithelial cells promotes the development of alcoholic liver disease in the liver	Kang ZHENG	Received

FRI-285	The benchmarks obeticholic acid and elafibranor show variable effects on NASH and hepatic fibrosis in diet-induced or chemically-induced animal models	FRANCOIS BRIAND	Received

SAT-286	Application of guidelines for fatty liver in two prospective cohorts of human immunodeficiency virus positive patients	Sila Cocciolillo	Received

SAT-287	A novel non-invasive index based on extracellular matrix markers can identify NAFLD patients with active disease and significant fibrosis: analysis of the CENTAUR study	Samuel Daniels	Received

FRI-288	Physiological levels of cardiotrophin-1 (CT-1) contribute to fasting-induced free fatty acid mobilization	David Carneros Trujillo	Received

SAT-288	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease	Victor de Ledinghen	Received

FRI-289	Effect of MSDC-0602K treatment on the metabolome of a diet-induced murine model	Jerry Colca	Received

SAT-289	Follow-up of NAFLD/NASH progression using an automated histological image analysis	Maxime De Rudder	Received

SAT-290	Association of liver inflammation and fibrosis score with non-invasive biomarkers in non-alcoholic fatty liver disease: Preliminary results from the MAST4HEALTH study	Konstantinos Apostolou-Karampelis	Received

FRI-290	The role of bile acids profile and insulin reistance for the prediction of gallstone disease in a prospective cohort of blood donors	Elton Dajti	Received

FRI-291	Glucokinase sensitizes hepatocarcinoma cells to the lipogenic activity of fructose and controls accumulation of lipid droplets and secretion of triglyceride-rich lipoproteins	Olivier Diaz	Received

SAT-291	Identifying NAFLD at the source: A novel approach to capturing nonalcoholic fatty liver disease in a diabetes practice	Amreen Dinani	Received

THU-291	Is non-alcoholic fatty liver disease a risk factor for chronic kidney disease?	Takemi Akahane	Received

SAT-292	Effectively reducing screen failure rate in non-alcoholic fatty liver disease clinical trial using the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST	Céline Fournier	Received

THU-292	The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes	Naim Alkhouri	Received

SAT-293	Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD	Céline Fournier	Received

FRI-293	Recipient PNPLA3 and TM6SF2 genotypes and risk of NAFLD folllowing liver transplantation	Speranta Iacob	Received

THU-293	Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis	María Teresa Arias Loste	Received

SAT-294	Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD	Roberta Forlano	Received

FRI-294	Mitochondrial GNMT-complex II is recovered by miR-873-5p targeting in NAFLD	David Fernández Ramos	Received

THU-294	Non-invasive measures of liver fibrosis in NAFLD is associated with cardiovascular risk	Sebastian Bachmayer	Received

FRI-295	Advanced glycation end products (AGEs) exacerbate NAFLD progression to liver fibrosis via receptor for AGEs (RAGE) in high fat fed mice	Hettya Kandage Dinali Helan Fernando	Received

THU-295	Nonalcoholic fatty liver disease is associated with QTc lengthening in the general population	Bubu Banini	Received

SAT-295	Diagnostic accuracy of non-invasive methods (NFS Score and FIB-4) for detecting advanced fibrosis: A validation study of NFS score and FIB-4 in a cohort of South Indian patients with NAFLD	Joe Francis	Received

SAT-296	Oxidized LDL is a distinctive biomarker of NASH independently of liver fibrosis in patients with NAFLD	Rocío Gallego-Durán	Received

FRI-296	Interaction between the soluble guanylate cyclase and the NLRP3 inflammasome in Kupffer cells: Implications for the anti-inflammatory actions of sGC stimulation in liver	Roger Flores-Costa	Received

THU-297	Prediction of NAFLD progression according to duration of exposure to obesity and diabetes: New approach to adapt therapeutic and research strategies	Pierre Bauvin	Received

FRI-297	Trans-signaling blockade induces mature-onset obesity and insulin resistance in mice via suppression of PPARalpha	Eithan Galun Prof.	Received

SAT-297	Prediction of incident severe liver disease in the general population using non-invasive scoring systems	Hannes Hagstrm	Received

SAT-298	MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study	Ma Ai Thanda Han	Received

FRI-298	Hypoxia-inducible factor 2 alpha drives lipid accumulation in human hepatocytes through the fatty acid translocase CD36	Carmelo García-Monzón	Received

THU-298	Clinical characteristics of NAFLD/NASH patients from gastroenterology and endocrinology clinics	Rachel Botchlett	Received

SAT-299	Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS=4) and significant fibrosis (F=2) in patients at risk of NASH	Axelle Louard	Received

FRI-299	Transcriptomic and epigenetic characterization of a NAFLD murine model	Antonio Gil-Gómez	Received

FRI-300	E2F2 mediated repression of fatty acid B-oxidation is mitigated through CREB1 in progressive non-alcoholic fatty liver disease	Francisco Gonzalez-Romero	Received

THU-300	Prevalence of NAFLD in patients with a first episode of stroke and impact on the mortality and severity at 3 months	Teresa Broquetas	Received

SAT-300	Prospective liver biopsy-based prevalence of non-alcoholic fatty liver disease and steatohepatitis among a large middle-aged population utilizing FibroScan, LiverMultiscan and magnetic resonance elastography to guide liver biopsy	Céline Fournier	Received

SAT-301	The FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST can efficiently screen for presence of at risk fibrotic NASH: Evaluation in an American cohort of patients screened for NAFLD	Céline Fournier	Received

SAT-302	Predicting the severity of hepatic steatosis and fibrosis by transient elastography and MRI-based techniques in adults patients with suspected NAFLD	Céline Fournier	Received

FRI-302	Impact of exercise on advanced fibrotic stage of NASH and liver carcinogenesis	Maria Guarino	Received

THU-302	Association between advanced fibrosis in fatty liver disease and overall mortality in terms of body size and body fat distribution	Goh Eun Chung	Received

SAT-303	Liver fibrosis together with PNPLA3 p.I148M variant affects quality of life in patients with non-alcoholic fatty liver disease: prospective liver stiffness-based study	Lena Heintz	Received

THU-303	Report from the trenches: Real-life challenges to recruitment and enrollment in NAFLD clinical trials	Amreen Dinani	Received

SAT-304	The association between visceral fat and evolution of patients with nonalcoholic fatty liver disease	Marta Hernández Conde	Received

THU-304	Modeling NAFLD-related disease progression among the PITER SVR12 cohort	Chris Estes	Received

FRI-304	Elafibranor and pioglitazone reduce NASH and fibrosis in a genetically-obese dietary-induced NASH mouse model	Katie Headland	Received

FRI-305	Long acting GLP-1/Glucagon co-agonist ameliorates steatosis, inflammation and fibrogenesis in a rodent model of NASH	Dorte Holst	Received

SAT-305	Alignment between physician-estimated versus objectively derived fibrosis scores in non-alcoholic steatohepatitis: Real-world evidence suggests clinicians underestimate disease severity in secondary care	Nathan Williams	Received

THU-305	Comparing perceptions of illness among patients with chronic liver disease	Izza Sattar	Received

FRI-306	RIP3 deficiency restores mitochondrial bioenergetics and function in experimental NAFLD	Tawhidul Islam	Received

THU-306	Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?	Roberta Forlano	Received

SAT-306	Autotaxin is a valuable biomarker for predicting liver fibrosis in patients with non-alcoholic fatty liver disease	Yasushi Honda	Received

THU-307	Whipple procedure increases the risk for non-alcoholic fatty liver disease	Jordan Goldstein	Received

FRI-307	Metadoxine prevents diet-induced non-alcoholic steatohepatitis in mice	Du Jinghua	Received

SAT-307	A direct comparative study among magnetic resonance elastography, vibration controlled transient elastography and shear wave elastography in patients with nonalcoholic fatty liver disease	Kento Imajo	Received

FRI-308	Inhibition of alpha 2A adrenergic receptors reduces liver inflammation in experimental NASH	Helen Jones	Received

THU-308	More than 4 times higher healthcare costs for end-stage liver disease patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis	Nandita Kachru	Received

SAT-308	The optimal cut-off points of FIB-4 index for predicting the incidences of HCC and extra-hepatic malignancies in biopsy-proven Japanese NAFLD patients	Takanori Ito	Received

THU-309	Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic	Atul Goyale	Received

FRI-309	Hepatitis B virus B and T cell specific responses are reduced in adults with a body mass index 35 and non-alcoholic fatty liver disease and in a mice model of NAFLD compared to adults with a BMI of 35 patients and normal animals	Shivali Joshi	Received

SAT-309	Prevalence of NAFLD and metabolic syndrome in rural and regional Victoria, Australia	William Kemp	Received

FRI-310	Alcohol dehydrogenase activity in liver and blood is altered in non-alcoholic fatty liver disease	Finn Jung	Received

THU-310	Non-alcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm	Jimin Han	Received

SAT-310	Real-world evaluation of NASH in US clinical practice: Underutilization of liver biopsy and liver imaging	NICOLE WICK	Received

THU-311	Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study	Ma Ai Thanda Han	Received

FRI-311	Gut lymphatic vascular disorder associates with severity of cirrhosis in non-alcoholic fatty liver disease	Savneet Kaur	Received

SAT-311	The PDGFR-beta containing PRTA-score is a novel non-invasive diagnostic algorithm for significant liver fibrosis in patients with viral, alcoholic, and metabolic liver disease	Joeri Lambrecht	Received

THU-312	Physician-recommended lifestyle interventions and associated effects among non-alcoholic steatohepatitis patients with and without cardiovascular-metabolic related comorbidities: A European real-world study	Nathan Williams	Received

FRI-312	Increased levels of bile acid in feces plays an important role in pathophysiology of nonalcoholic steatohepatitis	eva hortas	Received

THU-313	Differences between non-alcoholic steatohepatitis patient characterisation and management approaches: A multinational real-world study	Nathan Williams	Received

FRI-313	A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis	Kevin Klucher	Received

SAT-313	Exosomal miRNA analysis for classifying severity of disease in biopsy-proven NAFLD patients	Young-Sun Lee	Received

FRI-314	A novel semicarbazide-sensitive amine oxidase inhibitor, TERN-201, reduces NAS and fibrosis in rodent models of non-alcoholic steatohepatitis	Kevin Klucher	Received

SAT-314	Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid	Rosa Lombardi	Received

THU-314	Serum Zinc levels as a prognostic factor for extra-hepatic carcinogenesis in Japanese patients with non-alcoholic liver disease	Takanori Ito	Received

THU-315	Non-cirrhotic patients with non-alcoholic fatty liver disease have impaired quality of life: Independently predicted by body mass index, diabetes and liver stiffness	Benjamin Kadler	Received

FRI-315	Lipoprotein lipase deficiency in myeloid cells aggravates the progression of non-alcoholic steatohepatitis	Anja Koop	Received

FRI-316	Liver fetuin-A in activated macrophages is a key feature of non-alcoholic steatohepatitis in mice and humans	Nicolas Lanthier	Received

THU-316	Cognitive impairment or hepatic encephalopathy? A prospective cross-sectional study in patients with non-alcoholic fatty liver disease	Helena Katchman	Received

THU-317	The prescribing patterns and use of statins in patients with non-alcoholic fatty liver disease	Stephanie Watkins	Received

SAT-317	Fibroscan as a tool to improve cardiovascular disease stratification: Truth or myth?	Rui Magalhaes	Received

FRI-318	Effects of fatty acids and polyphenols from extra virgin olive oil in a murine animal dietary model knockout for the LDL receptor	Álvarez Amor Leticia	Received

SAT-318	Comparative accuracy of NAFLD fibrosis score, apri score, and FIB-4 score in predicting significant fibrosis in African Americans and Caucasians with non-alcoholic fatty liver disease	Hemnishil Marella	Received

THU-318	Elevated urinary bisphenol A levels are associated with nonalcoholic fatty liver disease among adults in the United States	Donghee Kim	Received

FRI-319	HEME oxygenase-1 mediates mitochondrial dysfunction in non-alcoholic steatohepatitis	Dongdong Li	Received

SAT-319	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients	Michael Praktiknjo	Received

THU-319	Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis	Saekyung Joo	Received

SAT-320	The use of the fatty liver index and fibroscan to determine the prevalence of non-alcoholic fatty liver disease in an Irish population	Louise Rabbitt	Received

THU-320	Evaluation of atherosclerosis and coronary artery stenosis of non-alcoholic fatty liver disease	Yoshihito Kubotsu	Received

FRI-320	TM6SF2 silencing impairs lipid metabolism and trafficking in HepG2 cells carrying the I148M PNPLA3 variant and MBOAT7 deletion	Miriam Longo	Received

SAT-321	Liver fibrosis scores predict mortality in the general population	Cristina Ripoll	Received

FRI-321	Hepatocyte expression of the protein kinase ERK5 regulates insulin sensitivity	Giulia Lori	Received

THU-321	Fluorodeoxyglucose perfusion and uptake in abdominal organs is associated with hepatic disease state in patients with non-alcoholic fatty liver disease	Alexander Kuo	Received

SAT-322	Comparison of point shear wave elastography (ElastPQ-pSWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD	Davide Roccarina	Received

FRI-322	Metabolic inflammation: The role of chemokine C-C motif ligan 2 in the crosstalk between liver tissue and muscle	Fedra Luciano	Received

THU-322	Statin use on development and progression of nonalcoholic fatty liver disease: A nationwide cohort study	Jung Il Lee	Received

THU-323	Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes	Rosa Lombardi	Received

FRI-323	Pegbelfermin (BMS-986036) reduces serum levels of secondary bile acids in patients with non-alcoholic steatohepatitis	Candy Zhu	Received

SAT-323	Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease	Chiara Rosso	Received

FRI-324	Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiologic characteristics and transcriptomic signature of the human disease	Jordi Gracia-Sancho	Received

THU-324	Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions	Peter Lykke Eriksen	Received

SAT-324	Sonic hedgehog immunohistochemistry is a tissue biomarker of ballooned hepatocytes	Michael Schild	Received

SAT-325	Implementation of a primary care shear-wave elastography-based pathway to identify non-alcoholic fatty liver disease patients with advanced fibrosis in a large North American urban population	Abdel-Aziz Shaheen	Received

THU-325	Regional liver function investigated by galactose positron emission tomography is reduced in patients with non-alcoholic steatohepatitis	Peter Lykke Eriksen	Received

FRI-325	rs641738 CT variant near MBOAT7-TMC4 increases risk of fibrosis, NASH, and HCC: A meta-analysis	Jake Mann	Received

SAT-326	Influence of NAFLD diagnosed by controlled attenuation parameterin patients of chronic hepatitis B with mildly elevated alt	MUHAMMAD ASIM	Received

FRI-326	Preclinical evaluation of endothelial dysfunction by peripheral artery tonometry and its correlations with untargeted metabolomic profiles	Mario Masarone	Received

THU-326	Relative fat mass: A new definition of obesity and NAFLD	Mariana Machado	Received

THU-327	Lifestyle modification leads to a significant decline in aminotrasnsferase activity even without weight reduction in children with non-alcoholic fatty liver disease	Anna Mania	Received

FRI-327	Liver mitochondrial hydrogen sulfide oxidation: From nutritional physiology to non-alcoholic fatty liver pathology	Ins Mateus	Received

THU-328	The prevalence of NAFLD in morbidly obese subjects revisited	Abraham Meijnikman	Received

SAT-328	Controlled attenuation parameter for evaluating liver steatosis in type 2 diabetes patients	Ioan Sporea	Received

SAT-329	Ethyl glucuronide inhair uncovers a high rate of harmful alcohol consumption in patients with presumed NAFLD	Katharina Staufer	Received

FRI-329	Comparison of seladelpar and combinations with liraglutide or selonsertib for improvement of fibrosis and NASH in a diet-induced and biopsy-confirmed mouse model of NASH	eva hortas	Received

SAT-330	Whole metabolome profiling identifiesthe combination of an eicosanoid, a bile acid and an androgen as a highly accurate marker of liver fibrosis in patients with non-alcoholic fatty liver disease	Felix Stickel	Received

THU-330	Biochemical liver tests reflect the genetic risk for fatty liver disease with increasing body weight but not with alcohol consumption	Elena Mueller	Received

SAT-331	Use of machine learning to predict diagnosis codes for non-alcoholic steatohepatitis in administrative healthcare data	Laura Telep	Received

FRI-331	Do N1-methylnicotinamide and nicotinamaide administration defferentially alleviated hepatic steatosis?	Makoto Nakamuta	Received

THU-331	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume	Benjamin H. Mullish	Received

THU-332	Healthcare resource utilisation, demographics, and comorbidities by diagnosis codes and histological stage in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in a large integrated healthcare delivery system in the U.S	Lisa Nyberg	Received

FRI-332	Effect of combined farnesoid X receptor agonist and angiotensin 2 receptor blocker on established liver fibrosis in rats	Tadashi Namisaki	Received

THU-333	The HSD17B13:TA (rs72613567) splice variant protects against severity of non-alcoholic fatty liver disease but not fibrosis	Rafael Paternostro	Received

SAT-333	Non-alcoholic steatohepatitis significantly decreases microsomal liver function in the absence of fibrosis, which allows the use of the 13C-aminopyrine breath test for its non-invasive detection	Wim Verlinden	Received

FRI-333	ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus	Serena Pelusi	Received

FRI-334	Cerium oxide nanoparticles present antilipogenic and anti-inflammatory effects in rats with diet-induced non-alcoholic fatty liver disease	Meritxell Perramon Corominas	Received

SAT-334	Liver steatosis in HIV-positive patients with and without HBV coinfection accessing care in a programmatic setting in Africa	Giovanni Villa	Received

THU-334	PNPLA3 rs738409 CG variant predicts liver-related events and death in non-alcoholic fatty liver	Salvatore Petta	Received

SAT-335	A simple biomarker panel predictive of advanced fibrosis in patients with non-alcoholic steatohepatitis	Zobair Younossi	Received

THU-335	FXR rs35724 CG variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver	Salvatore Petta	Received

SAT-336	lLver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease	Ming-Hua Zheng	Received

FRI-336	Lack of CCL2 limits the development of HCC in a model of obesity-associated carcinogenesis	Benedetta Piombanti	Received

THU-336	Possible ways of concomitant hypothyroidism effect on the course of nonalcoholic fatty liver disease	Vasyl Prysyazhnyuk	Received

THU-337	Cardiovascular risk factors and fibrosis severity in NAFLD: is there a link?	Davide Roccarina	Received

SAT-337	Evaluation of anti-fibrotic properties of OCA and INT-767 in an in vitro system of NAFLD	Beatrice Anfuso	Received

THU-338	Prevalence and dynamics of NAFLD-associated fibrosis among HIV from first presentation to last follow-up	Caroline Schmidbauer	Received

FRI-338	Mitochondrial uncoupler HU6 reduces hepatic oxidative stress in the DIAMOND(TM) mouse model, thus abrogating NASH development	Francisco Portell	Received

SAT-338	Oral arginine supplementation attenuates the progression of steatosis to non-alcoholic steatohepatitis through preventing translocation of bacterial endotoxin	Anja Baumann	Received

SAT-339	Socioeconomic deprivation is associated with non-response to lifestyle interventions in non-alcoholic fatty liver disease	Kris Bennett	Received

FRI-339	Clinical translatability of a diet-induced obese mouse model of non-alcoholic steatohepatitis	Kristoffer Rigbolt	Received

THU-339	The relationship between the PNPLA3, TLL1 polymorphism combination and advanced fibrosis in Japanese patients with non-alcoholic fatty liver disease	Yuya Seko	Received

FRI-340	In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models of liver injury and metabolic disease	Manuel Roqueta-Rivera	Received

THU-340	Epidemiology of NAFLD and advanced fibrosis in the French general population: A population-based cohort study in 118,664 subjects (NASH-CO study)	Lawrence Serfaty	Received

FRI-341	Sexual aspects of liver metabolism: A computational approach	Damjana Rozman	Received

THU-341	Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load	Amir Shlomai	Received

SAT-341	MET409, an optimized sustained FXR agonist, was safe and well-tolerated in a 14-day phase 1 study in healthy subjects	Hubert Chen	Received

SAT-342	Morphometric collagen analysis discerns anti-fibrotic effects of INT-767 and OCA in NASH mouse models using second harmonic generation imaging	Li Chen	Received

FRI-342	Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis	Yasuhiko Sawada	Received

THU-343	Systematic review: Patient reported quality of life outcomes in non-alcoholic fatty liver disease: Effect of disease severity and duration	Humaira Ud-Din	Received

SAT-343	Alagebrium ameliorates NAFLD progression in mice fed a high advanced glycation end products diet via direct inhibition of Kupffer cells and indirect inhibition of hepatic stellate cell activation	Hettya Kandage Dinali Helan Fernando	Received

FRI-343	NEDDylation inhibition as a new potential therapy of non-alcoholic fatty liver disease	Marina Serrano-Macia	Received

FRI-344	Preclinical characterization of FM101, a first-in-class A3 adenosine receptor modulator for the treatment of non-alcoholic steatohepatitis	Changho Shon	Received

SAT-344	MSDC-0602K targets the mitochondrial pyruvate carrier to treat non-alcoholic steatohepatitis	BRIAN FINCK	Received

THU-344	The influence of non-alcoholic fatty liver disease on a two year prognosis of the patients with stable coronary heart disease depending on SYNTAX score II	Iryna Vakalyuk	Received

SAT-345	Novel mitochondrial pyruvate carrier modulators to treat non-alcoholic steatohepatitis and insulin resistance	Brian Finck	Received

THU-345	Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD	Stephanie Watkins	Received

SAT-346	Icosabutate induces a potent reduction in hepatic oxidative stress in rodent models of metabolic stress and fibrosing NASH	David Fraser	Received

FRI-346	The effect of exercise training and canagliflozin on hepatic lipid metabolism of nonalcoholic fatty liver disease	Kenichi Tanaka	Received

THU-346	Plasma ApoE levels are associated with non-alcoholic fatty liver disease: the PREVEND cohort study	Eline H. Wouters-Van Den Berg	Received

THU-347	Economic and clinical burden of non-alcoholic steatohepatitis in patients with type II diabetes in the United States	Zobair Younossi	Received

SAT-347	MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study	Stephen Harrison	Received

THU-348	Patients with non-alcoholic steatohepatitis experience severe impairment of health related quality of life	Zobair Younossi	Received

SAT-348	Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study	Wolf Peter Hofmann	Received

SAT-349	Improvement of hepatic inflammation and fibrosis independently of weight loss from a short, individualized, web-based exercise program in patients with NAFLD	Yvonne Huber	Received

FRI-349	Development of humanized nonalcoholic steatohepatitis model using chimeric mice with highly repopulated humanized livers	Chise Tateno	Received

SAT-350	YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis	Junhwan Kim	Received

FRI-351	DNA methylation pattern of TM6SF2 influences NAFLD progression in genotype-dependent manner	Burge Ulukan	Received

SAT-351	Biomarkers and clinical characteristics associated with nonalcoholic steatohepatitis fibrosis progression in the CENTAUR study	Nicolas Lanthier	Received

FRI-352	Inflammation provokes hepatic but not adipose tissue diacylglycerol acyltransferase 2 expression and concomitant triglyceride synthesis in an experimental non-alcoholic fatty liver disease	Balasubramaniyan Vairappan	Received

SAT-353	The effect of metformin on hepatic fatty acid partitioning; an investigation using human in vivo and in vitro models	Thomas Marjot	Received

FRI-354	Novel Gubra Amylin NASH diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis	Sanne Veidal	Received

SAT-354	Aramchol, SCD1 inhibitor, improves liver glucose homeostasis in NASH	Luba Litinetsky	Received

FRI-355	Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment	Axelle Louard	Received

SAT-355	Fatty liver trends in Southern Italy: Mediterranean or Americanized lifestyle habits?	Emilio Molina Molina	Received

FRI-356	Single cell peripheral innate and adaptive immune signature of non-alcoholic steatohepatitis by cytometry time of flight	Kathryn Waller	Received

SAT-356	Anti-metabolic, anti-inflammatory and anti-fibrotic properties of ART-648, a novel phosphodiesterase 4 inhibitor as a potential clinical candidate for non-alcoholic steatohepatitis	Hiroshi Nagabukuro	Received

SAT-357	Tropifexor, a farnesoid X receptor agonist for the treatment of nonalcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR	Arun Sanyal	Received

FRI-357	Fibrinogen-like protein 2 aggravates non-alcoholic steatohepatitis by enhancing inflammatory signaling in macrophages	Xiaojing Wang	Received

FRI-358	Differentiation of glucagon and glucagon-like peptide-1 effects on hepatocytes	Xiaozhen Wang	Received

SAT-358	Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials	Yuya Seko	Received

FRI-359	Ductular reaction predicts the progression of non-alcoholic fatty liver disease	Ramy Younes	Received

SAT-359	Pharmacokinetics and safety of pegbelfermin (BMS-986036) administered in the abdomen and upper arm to normal, overweight, and obese healthy participants	Candy Zhu	Received

FRI-360	The role of Paneth cells in the pathogenesis of non-alcoholic fatty liver disease: A potential gut microbiota-associated mechanism	Saisai Zhang	Received

FRI-361	Impact of cardiovascular complications on patients outcome after orthotopic liver transplantation	Niklas Aehling	Received

FRI-362	Exercise training for liver transplant candidates	Bandar Aljudaibi	Received

THU-363	Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression	Karin Kwikkers	Received

FRI-363	Iron metabolism imbalance is associated with increased mortality following orthotopic liver transplantation	Edouard Bardou-Jacquet	Received

THU-364	Liver cT1 predicts clinical outcomes in patients with chronic liver disease	Arjun Jayaswal	Received

FRI-364	Frequency and impact of discordance between pre-transplant imaging and explant histology on post liver transplant outcomes for patients with hepatocellular carcinoma	Amine Benmassaoud	Received

FRI-365	Efficacy of combined partial hepatectomy and cyst fenestration on health-related quality of life in polycystic liver disease	Lucas H.P. Bernts	Received

THU-365	Adeno-associated virus-serotype-specific transduction patterns in mice and non-human primates liver tissue: Implications for therapeutic efficacy	Anna Majowicz	Received

FRI-366	Portal vein thrombosis in patients on the waiting list for liver transplantation: A single center cohort study	Xavier Verhelst	Received

FRI-367	Pre-liver transplant profile of cardiovascular risk factors and its impact on early post-transplant outcome	Claudia Chialà	Received

THU-367	Linking diabetic cardiovascular disease with non-alcoholic fatty liver disease through L-carnitine: A hyperpolarized MRS study	Dragana Savic	Received

THU-368	Multimodal pre-clinical imaging of liver inflammation and fibrosis	Anja Schmidt-Christensen	Received

THU-369	Efficacy and safety of endoscopic ultrasound-guided liver biopsies in parenchymal liver diseases: A systematic review and meta-analysis	Anup Shah	Received

FRI-369	The role of adipose tissue in metabolic and cardiovascular complication after liver transplantation	Daria DAmbrosio	Received

FRI-370	Application of an extended-release tacrolimus formulation allows dose reduction and stabilizes graft function after liver transplantation	Alexandra Frey	Received

THU-370	Quantification of hepatic metal overload by laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI)	Ralf Weiskirchen	Received

FRI-371	Correlation between classification of circulating tumor cells in peripheral blood and early recurrence in patients with hepatocellular carcinoma after liver transplantation	Binsheng Fu	Received

THU-371	Modulation of H3K27 methylation by EZH2 and UTX/JMJD3 small molecules inhibitors impacts on proliferation and differentiation of hepatic progenitor cells and differentiated hepatocytes plasticity	Laura Belloni	Received

SAT-371	Alleviation in NK cells cytotoxicity following inhibitions of Neuroligin-4 (NLG4) receptor by recombinant beta-neurexin involving IL-4 pathway	Johnny Amer	Received

SAT-372	High prevalence of anti HLA Class II de novo donor-specific antibodies during rejection after liver transplantation	Jordi Colmenero	Received

THU-372	Exosomes from human umbilical cord mesenchymal stem cells promote liver regeneration in aged mice after major hepatectomy via activating sirtuin1 pathway	Liang Chen	Received

FRI-372	Next generation sequenzing outperforms standard microbiological cultivation for detection of bacteria in the biliary tract in patients with ischemic type biliary lesions and/or anastomotic stricture	Bjrn Grobe	Received

FRI-373	Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation	Sandra Guiral Foz	Received

THU-373	IL-6 trans-sginaling controls liver regeneration after partial hepatectomy	nastaran Fazel Modares	Received

SAT-373	Peritoneal mucosal-associated invariant T cells functionally differ from their exhausted circulating counterparts in decompensated cirrhosis	Oluwatomi Ibidapo-Obe	Received

SAT-374	Interleukin 35 exerts its suppressive function in chronic liver failure through the induction of an immunosuppressive HLA-GCD4 regulatory T -cell population	Wafa Khamri	Received

FRI-374	Von Willebrand factor independently predicts mortality on the waitlist for liver transplantation and facilitates additional risk stratification in low MELD patients	Georg Gyoeri	Received

THU-374	The INCRNA H19-dervied MIR-675 promotes liver necroptosis by targeting fadd	Maytal Gefen	Received

FRI-375	Direct oral anticoagulants are safe and effective in patients after liver/kidney transplantation	Adam Herber	Received

THU-375	Transcription factor TRIM33 controls liver progenitor cell towards hepatocyte differentiation through synergizing with SMAD2/3 following massive parenchymal loss	Tao Lin	Received

SAT-375	Therapeutic interleukin 4 modulates monocyte dynamics and accelerates repair and regeneration following acute liver injury	Ruairi Lynch	Received

FRI-376	Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival	Federica Invernizzi	Received

THU-376	A viral mediated liver repopulation assay without the use of transgenic animals	Wei-Yu Lu	Received

SAT-376	Bile acids induce STAT3 and repress FOXP3 expression in hepatic CD4 lymphocytes under cholestatic conditions	Alexander Miethke	Received

SAT-377	Significant reductions in intrahepatic Mucosal Associated Invariant T cells with increased terminal activation marker expression amongst NAFLD patients following a 12 week aerobic exercise program: a paired liver biopsy study	Sara Naimimohasses	Received

FRI-377	Survival outcome after liver transplantation in US patients with hepatocellular carcinoma	Mohamed Saleh Ismail	Received

THU-377	Systemic blood pressure is not associated with hepatic perfusion and metabolic activity by 18F-FDG PET in patients with NAFLD	Souvik Sarkar	Received

SAT-378	The NIF mouse as a model for acute, late stage non-alcoholic steatohepatitis	Julia Nilsson	Received

FRI-378	Should we change the allocation policy for NASH patients?	Assaf Issachar	Received

THU-378	Messenger RNA transcriptome profiling reveals a distinct phenotype of human bone marrow mesenchymal stem cell-derived hepatocytes	Dongyan Shi	Received

THU-379	Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycine	Hongbo Shi	Received

SAT-379	Myeloid cells require gp130 signalling for protective anti-inflammatory functions during sepsis	Tobias Otto	Received

SAT-380	Liver-resident memory CD8 T cells do not egress into hepatic venous blood	Sergio Rodriguez Tajes	Received

FRI-380	Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma	So-Hyun Kim	Received

THU-380	DLL4 restores damaged liver by protecting hepatocytes and enhancing cholangiocyte differentiation	Jun Li	Received

THU-381	Characterization of regeneration in chronic hepatitis B before and after entecavir treatment in 20 patients	Ian Wanless	Received

SAT-381	TAA-specific CD8 T-cell responses are inefficiently induced in hepatocellular carcinoma	Catrin Tauber	Received

FRI-382	Biological assessment comprising alpha-fetoprotein, albumin-bilirubin score and C-reactive protein provides better prognostic competence than tumor size criteria in liver transplant patients with HCC	Arno Kornberg	Received

THU-382	Use of facility-based provider initiated testing and counselling approach to ascertain viral hepatitis C status in high burden populations in Nigeria	Chukwuemeka Agwuocha	Received

SAT-382	Crosstalk between liver NKT cells and liver sinusoidal endothelial cells	Abdallah Yassin	Received

SAT-383	Human mesenchymal stem cells-derived exosomes attenuate liver ischemia/reperfusion injury by up regulation of notch-1-related autophagy in CD4 T cell	Xiaomei Zhang	Received

THU-383	Dried blood spots: A useful tool for virologically caracterising the hepatitis C virus epidemic	Elisa Martro Catala	Received

FRI-383	Role of traditional cardiovascular risk factors in predicting long term survival after liver transplantation	Anoop Koshy	Received

FRI-384	Early cardiovascular mortality following liver transplantation: 30-year temporal trends from the Australian & New Zealand liver transplant registry	Anoop Koshy	Received

THU-384	Clinical Performance of determine TM HBsAg 2 rapid test for hepatitis B detection	Ana Avellon	Received

THU-385	Targeted screening for hepatitis C and predictors of advanced liver disease in the birth cohort in a tertiary primary care clinic	Bersoux Sophie	Received

FRI-385	Use of machine learning algorithms to predict HCC recurrence after liver transplantation: A proof of concept	Phillipe Abreu	Received

SAT-385	Production and characterization of humanl liver extracellular matrix hydrogels for in vitro culture of distinct human primary liver cell populations	Niki Alevra Sarika	Received

FRI-386	Impact of acute-on-chronic liver failure on survival after liver transplantation	Sebastián Marciano	Received

SAT-386	Insulin resistance in NK cells of F4 fibrosis inhibit mTOR expressions and are associated with decreased F-actin and killing ability in NASH patients	Johnny Amer	Received

THU-386	Interim results of hepatitis prevention, control and elimination program in Ulaanbaatar, Mongolia	Purevjargal Bat-Ulzii	Received

FRI-387	Risk factors associated with early post-operative acute kidney injury requiring renal replacement therapy following liver transplantation	Jeremy Nayagam	Received

THU-387	Eliminating viral hepatitis C in Belgium: A mathematical model of the micro-elimination approach	Dana Busschots	Received

FRI-388	Hepatitis C iInfected liver grafts transplanted into non-infected recipients are safe in the era of highly effective direct-acting antiviral therapy	Heather ODell	Received

SAT-388	How to infuse heterologous human adult liver-derived progenitor cells safely?	Louise Coppin	Received

THU-388	Annual healthcare costs double for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients who progress to advanced liver disease: A multivariable analysis of German real-world data	Nandita Kachru	Received

THU-389	Assessment of hepatitis C screening strategies in different community settings in a Canadian metropolitan area	Camelia Capraru	Received

SAT-389	Obeticholic acid reduces matrix metalloproteinases activity via iNOS modulation in hepatic ischemia/reperfusion injury	Laura Giuseppina Di Pasqua	Received

FRI-389	Impact of coronary artery disease on long term mortality after liver transplantation	Samarth Patel	Received

THU-390	Results of a birth cohort hepatitis C screening program in an academic emergency department in Canada	Camelia Capraru	Received

SAT-390	Dengue virus protein NS3 activates hexokinase activity in hepatocytes to support virus replication	Olivier Diaz	Received

FRI-390	Management of dyslipidemia after liver transplantation	Samarth Patel	Received

FRI-391	Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are markers for biliary damage and predict graft survival	Christian Rupp	Received

THU-391	Impact of early screening and treatment of hepatitis C virus and improvements in risk reduction on HCV transmission among HIV-infected men who have sex with men in France: A modeling approach	Mathieu Castry	Received

SAT-391	The influence of Caveolin-1 on hepatocyte metabolism	Mei Han	Received

THU-392	Building capacity within a hepatitis C treatment model. the validation process for a hepatitis C pre-treatment pharmacist assessment complex intervention toolkit	Miriam Coghlan	Received

FRI-392	Sarcopenia associated with worse pre-transplant psychosocial status and predicted post-transplant diabetes	Yael Milgrom	Received

SAT-392	Dickkopf-1 from hepatocellular carcinoma cells promotes the angiogenic potential of endothelial cells by activating the VEGFR-2 signaling pathway	Bora Jin	Received

SAT-393	Melatonin attenuates dysregulation of the circadian clock pathway in liver fibrosis and progression to hepatocarcinoma	Diana Isabel Sánchez	Received

FRI-393	Arterial stiffness in the assessment of cardiovascular risk after liver transplantation	Lydia Sastre	Received

THU-393	HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort	David Mackie	Received

THU-394	Cancer risk among people with HIV, HBV, and/or HCV infections	Maryam Darvishian	Received

FRI-394	Impact of early kidney dysfunction in the incidence of major cardiovascular events after liver transplantation	Lydia Sastre	Received

SAT-395	Bone marrow-mesenchymal stem cells of cirrhosis patients show insulin resistance and bioenergetic exhaustion	Deepanshu Maheshwari	Received

THU-395	Hepatitis C elimination by enhancing care and treatment among HIV co-infected individuals (the co-EC study): Real world evidence of decreasing HCV incidence and prevalence	Joseph Doyle	Received

FRI-395	Etiology of liver disease affects weight gain after liver transplantation	Mohammad Siddiqui	Received

FRI-396	Hypoadiponectinemia as a predictor of cardiovascular events in liver transplant recipients	Mohammad Siddiqui	Received

THU-396	Hepatitis C screening among the population of Georgia within the national elimination program	Sophia Surguladze	Received

SAT-396	Heat activation of hepatocytes is sufficient to account for post radiofrequency ablation induced tumorigenesis	Aurelia Markezana	Received

THU-397	Screening strategies for hepatitis C virus elimination in Italy	Ivane Gamkrelidze	Received

SAT-397	HIC-5 and GARP expression is upregulated by hydrogen peroxide and TGF beta in primary human hepatic stellate cells cultured on decellularized human liver 3D ECM scaffolds	Simona Onali	Received

FRI-397	Sepsis is a major risk factor for delirium post liver transplantation	Oliver Tavabie	Received

SAT-398	Pterostilbene reduces liver steatosis associated with obesity	Saioa Gómez-Zorita	Received

THU-398	Circulating HCV resistant strains may result in long-term challenges to HCV elimination: A modeling study	Ilias Gountas	Received

FRI-398	Impact of sarcopenia and myosteatosis on post-transplant complications and survival	Daniele Tavano	Received

THU-399	First Belgian hepatitis E seroprevalence study shows low stable birth-cohort specific seroprevalence until 2014, with recent 2016-2018 increase in single centre estimates	Erwin Ho	Received

FRI-399	Impact of a temporary cardiac arrest in a brain dead liver donor on liver transplantation results	Elodie Timsit	Received

SAT-399	The profile on intracellular gangliosides correlates with the malignant phenotype of cholangiocarcinoma cells and modulates cells adhesion	Chiara Raggi	Received

THU-400	Alanine-aminotransferase and 20-year risk of liver disease, cancer, ischemic heart disease, and diabetes in a Danish general population sample aged 30-49 years	Morten Daniel Jensen	Received

SAT-400	IL-1 beta-mediated macrophage-hepatocyte crosstalk upregulates hepcidin under physiologic low oxygen levels	Ins Silva	Received

FRI-400	Poor long term outcome of patients undergoing liver transplantation with preterminal renal dysfunction	Marcel Touma	Received

THU-401	Changes in mortality due to chronic liver diseases in Spain during the period 2002-2016	Matthew Keys	Received

FRI-401	Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis C	Chung Sang Tse	Received

SAT-401	Necroptosis signaling molecules regulate hepatic stellate cell activation via MLKL oligomerization-cell death independent pathway	Sang Bong Ahn	Received

THU-402	Tailored message interventions using social marketing approach versus traditional message for increasing participation in viral hepatitis screening for Japanese workers	Masaaki Korenaga	Received

FRI-402	Outcomes after liver transplantation for argininosuccinate lyase deficiency: A longitudinal study	Nipun Verma	Received

THU-403	The consensus hepatitis C cascade of care: Methodology and initial findings from three countries	Jeffrey V Lazarus	Received

FRI-403	Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome	Elia Vettore	Received

SAT-403	Polycyclic aromatic hydrocarbons can trigger a hepatocyte release of cytotoxic extracellular vesicles	Nettie Van Meteren	Received

SAT-404	Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients	Giulia Morsica	Received

FRI-404	Multicenter experience evaluating outcomes of HCV-seropositive donors to HCV-seronegative recipients liver transplantation	Karn Wijarnpreecha	Received

THU-405	Complications of chronic hepatitis B: Prevalence and disparities in a US health system cohort 2006-2016	Lora Rupp	Received

FRI-405	Predictors of outcomes for patients with non-alcoholic steatohepatitis undergoing liver transplantation in the United States	Zobair Younossi	Received

SAT-405	Genomic expression in circulating PBMCs of patients with hepatocellular carcinoma: Effect of ablative treatment	Palmieri Vincenzo	Received

SAT-406	Elevated biliary cholesterol in spite of hepatic ABCG5/G8 deficiency: Biliary lipid secretion in conditional knock-out mice	Susanne N Weber	Received

THU-406	Cost-effectiveness analysis of treat all guidelines for chronic hepatitis C in Brazil	Everton Macdo Silva	Received

THU-407	Implementation of a hepatitis C testing and linkage to care program in the Philadelphia jail system	Lora Magaldi	Received

SAT-407	The Wilsons disease mouse (Atp7b-/-) has profound alterations in the hepatic metabolome and improved insulin sensitivity	Ruth Wooton-Kee	Received

FRI-407	Elevating liver disease management in Egypt: A Project ECHO experience	Noha Abdelgelil	Received

THU-408	Screening for viral immunity prior to immunosuppressive or biologic therapy	Richard Manfready	Received

FRI-408	Self-stigma among patients with hepatitis B and C and its association with delayed diagnosis and treatment	Shireen Abu Elhija	Received

FRI-409	Measuring the impact of a new liver specialist nursing service on patient care	Dianne Backhouse	Received

SAT-409	Hepatic vein arrival time assessed by contrast-enhanced ultrasound in the non-invasive evaluation of portal hypertension	Irene Andaluz García	Received

THU-409	Progress on scaling up testing and treatment for hepatitis C elimination in Punjab, Pakistan: Hepatitis prevention and treatment program	Ammara Naveed	Received

SAT-410	Higher spleen iron content estimated by MRI T2 signal is associated with lower insulin-resistance in patients with dysmetabolic iron overload syndrome	Edouard Bardou-Jacquet	Received

THU-410	Hepatitis B prevention of mother to child transmission integrated into antenatal care services in Mozambique	Aude Nguyen	Received

FRI-410	Health literacy in outpatients with liver cirrhosis	Palle Bager	Received

FRI-411	Nurse-led out-patient-clinic for patients with cirrhosis	Hanne Bennick	Received

SAT-411	Clinical comparison and conversion of international normalized ratio and prothrombin index	Paul Cales	Received

THU-411	Effectiveness of direct: Acting antivirals for the treatment of viral hepatitis C in Rwanda	alida Ngwije	Received

SAT-412	The utility of the enhanced liver fibrosis test in alcoholic liver disease	Declan Connoley	Received

THU-412	Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection: Results from the treatment as prevention for hepatitis C (Trap HepC) program	Sigurdur Olafsson	Received

FRI-412	A collaborative approach to increase access to hepatitis C treatment for the homeless population in Cornwall	Helen Hampton	Received

THU-413	Service delivery for hepatitis C care: A systematic review and meta-analysis	Ena Oru	Received

FRI-413	Integrating nurses in the management and care of patients with NAFLD: Better adherence and outcomes	Anna Marie Hefner	Received

SAT-413	Selected cytokines associated with chronic hepatitis b histological activity and fibrosis: A 78-week prospective study	Xiao-Qin Dong	Received

FRI-414	The impact of self and parental perception of body image on management in patients with NAFLD	Anna Marie Hefner	Received

SAT-414	Baveno VI principle for noninvasive assessment of high risk varices is also applicable with shear wave elastography	Oana Farcau	Received

THU-414	Low rate of treatment uptake amongst recently released prisoners with active HCV infection	Timothy Papaluca	Received

THU-415	Changing patterns of liver disease in Wales: First results from the Wales liver disease registry	Andrew Yeoman	Received

SAT-415	High levels of basement membrane remodelling (C4M) and low activity of wound healing (FPA) reflect fibrosis in alcoholic liver disease	Natasja Gudmann	Received

FRI-415	People are scared: what they dont know dont hurt them. A qualitative exploration of reasons for low uptake of hepatitis C virus testing in an English prison	Kathryn Jack	Received

THU-416	Use of telemedicine as a cost-effective program to achieve microelimination of hepatitis C virus infection among patients in a public healt care system in a low-income country	JOSE LUIS PEREZ HERNANDEZ	Received

FRI-416	Assessment of written patient information pertaining to cirrhosis and its complications: A pilot study	Lea Ladegaard Grnkjr	Received

SAT-416	Transient elastography in normal pregnancies: A prospective cohort study	Hannes Hagstrm	Received

SAT-417	Serum levels of keratin 19 fragments (CYFRA 21-1) are elevated in advanced liver disease and predict poor survival	Karim Hamesch	Received

FRI-417	Impact of a nurse educational program and accessibility in the management of patients with hepatocellular carcinoma under systemic treatment	Neus Llarch	Received

FRI-418	Evaluating patients experience in liver transplantation: Role of the focus group technique	Eva Lopez-Benages	Received

THU-418	Community-based screening for significant liver fibrosis among apparently asymptomatic adults in Delhi	ARCHANA RAMALINGAM	Received

SAT-418	Splenic stiffness measurement using the ultrasound-fusion method	Masashi Hirooka	Received

THU-419	Prevalence of hepatitis B and C virus infections in Mongolian children and adolescents	Khishigtogtokh Sereenendorj	Received

SAT-419	Endotrophin, a fragment of collagen type VI formation (PRO-C6) is associated with progression free survival and mortality in patients with hepatocellular carcinoma	Signe Holm Nielsen	Received

FRI-419	Is a lack of patient awareness holding back self-management of NAFLD?	Bronwen Williams	Received

THU-420	Examination of patient and provider perceptions of hepatitis C care in Rwanda	Janvier Serumondo	Received

SAT-420	The value of liver stiffness to platelet ratio and liver stiffness to spleen diameter to platelet ratio score compared with hepatic venous pressure gradient to predict the portal hypertension in patients with alcoholic and viral cirrhosis	Soung Won Jeong	Received

FRI-420	A nurse-led advice and lifestyle intervention shows high levels of patient-reported satisfaction and motivation in community-based management of NAFLD	Bronwen Williams	Received

THU-421	Lower alcohol taxes are associated with increased liver transplant listing	Nicole Shen	Received

SAT-421	A novel score to patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort	Asgeir Johannessen	Received

FRI-422	Genetic and pathophysiological factors leading to deficient acyl-CoA oxidase 2 (ACOX2) activity in hepatocytes, an alteration which causes oxidative and endoplasmic reticulum stress in liver cells	Marta Alonso-Peña	Received

THU-422	Referral, treatment uptake and self-reported barriers in drug users diagnosed with active hepatitis C attending a low-threshold methadone program in Lisbon	Mario Jorge Silva	Received

SAT-423	Spleen extracellular volume fraction and platelet count/spleen volume ratio are accurate non-invasive markers of portal hypertension	Christina Levick	Received

THU-423	Patient group monitoring of implementation of WHO viral hepatitis C recommendations: Identifying the gaps between policy and practice in Europe	Adam Palayew	Received

FRI-423	Role of antithrombin deficiency in splanchnic vein thrombosis	Anna Baiges	Received

THU-424	HCV care cascade of PWIDs reached within the Global Fund needle and syringe program in Georgia	Ketevan Stvilia	Received

FRI-424	Estrogen-containing oral contraceptives are associated with polycystic liver disease severity in pre-menopausal patients	Lucas H.P. Bernts	Received

SAT-424	Spleen transient elastography and suprahepatic vein dumping index can be useful to identify patients without acute and chronic response to beta-blockers	Elba Llop	Received

FRI-425	Maintenance therapy for Wilson disease with zinc: A comparison between zinc acetate and alternative zinc salts	Michelle Camarata	Received

SAT-425	Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis	Rocio Macias	Received

SAT-426	Abnormal liver function tests: Current waiting times and comparison to iLFTs	Iain Macpherson	Received

THU-426	Further validation of a liver traffic light test as a prediction model for survival and development of serious liver-related events	Rochelle Sylvester	Received

FRI-426	Overexpression of c-Jun N-terminal Kinase-1 coincides with the acquisition of cholangiocytic markers in experimental cholangiocarcinoma	Chaobo Chen	Received

THU-427	A community-based fast-track seek-test-treat program to enhance diagnosis and linkage to care for hepatitis C infection among people who inject drugs in Athens, Greece (ARISTOTLE HCV-HIV program)	Vana Sypsa	Received

FRI-427	Liver humanized mouse as models for human metabolic liver diseases	Raghuraman Chittoor Srinivasan	Received

SAT-427	The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy	Federico Ravaioli	Received

THU-428	Routine point of care antenatal screening of hepatitis B virus in windhoek, Namibia: Feasibility of implementation	Cynthia Tamandjou	Received

SAT-428	Prediction of liver stiffness by serum indexes in HCV-infected patients with or without HIV coinfection	Nicolás Merchante	Received

FRI-428	Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension	Simone Di Cola	Received

SAT-429	Von Willebrand factor a noninvasive serum biomarker of portal pressure in cirrhosis: Evidence in human and rodent	Xiaolong Qi	Received

FRI-429	Impact of allelic variants of platelet receptors and coagulation system genes in the development of clinical manifestations of Wilsons desease	Saglara Fastovets	Received

THU-429	Serial testing with the enhanced liver fibrosis test and liver stiffness is cost-effective for detection of advanced alcoholic liver disease in primary care	Maja Thiele	Received

FRI-430	Preclinical validation of copper 64 as a translational tool for evaluating the pharmacodynamics of VTX-801 genen therapy in Wilsons disease	Gloria Gonzalez	Received

SAT-430	Spleen stiffness measured with ElastPQ point shear wave elastography has a good performance in predicting clinically significant portal hypertension in patients with primary sclerosing cholangitis	Davide Roccarina	Received

THU-430	Changing prevalence of aetiological factors among Australians hospitalized for cirrhosis	Patricia Valery	Received

SAT-431	Spleen stiffness measurement with ElastPQ point shear wave elastography has an excellent performance in predicting the presence of clinically significant portal hypertension in primary biliary cholangitis	Francesca Saffioti	Received

THU-431	The burgeoning growth in cirrhosis-related hospitalization in Australia, 2008-2016	Patricia Valery	Received

FRI-431	Clinical spectrum of congenital hepatic fibrosis in children: 15 year experience from a tertiary care centre in north India	Vybhav Gummadi	Received

FRI-432	Current long-term outcome of 302 patients with noncirrhotic nontumoral extrahepatic portal vein thrombosis	Guohong Han	Received

THU-432	Viral sustained response in chronic hepatitis C did not reduce short term heatlh expediture	Mercedes Vergara Gómez	Received

SAT-433	Portal venous velocity and platelet count as a simple non invasive tool to rule out the presence of varices needing treatment in patients with compensated cirrhosis	Francesco Santopaolo	Received

FRI-433	Bevacizumab for the treatment of liver involvement in patients with hereditary hemorrhagic telangiectasia	Assaf Issachar	Received

THU-433	Availability of information in drug labels for appropriate prescribing in patients with hepatic impairment	Rianne Weersink	Received

THU-434	Poorly chosen upper limits of normal for alanine aminotransferase may burden the patient and health system unnecessarily	Johannes Wiegand	Received

SAT-434	Liver stiffness measurement by transient elastography for the prognosis of hepatic carcinoma, decompensation, and death in patients with chronic liver diseases: A systematic review and meta analysis	Yue Shen	Received

FRI-434	Role of next generation sequencing in the etiological diagnosis of splanchnic venous thrombosis	Marta Magaz	Received

THU-435	A threshold analysis for the cost-effectiveness of hepatitis B and hepatitis C testing in emergency departments in the UK	Jack Williams	Received

SAT-435	Quantitative MRCP imaging (MRCP): Accuracy, repeatability and reproducibility evaluation in healthy and liver disease patients	gary woodward	Received

FRI-435	Progression to cirrhosis is not infrequent in patients with Wilsons disease despite treatment	Zoe Mariño	Received

THU-436	The cost-effectiveness of one-time birth cohort screening for hepatitis C as part of the National Health Service health check programme for 40 to 74 year olds in England	Jack Williams	Received

FRI-436	Congenital porto-systemic shunts in children: Preliminary results from the IRCPSS	Valérie Mclin	Received

SAT-436	Inhibition of autophagy prolongs recipient survival through accelerating CD8 T-cell apoptosis in a rat liver transplantation model	Xiaolong Chen	Received

THU-437	The Global Epidemiology on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus: A systematic review and meta-analysis	Zobair Younossi	Received

SAT-437	An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro	Alexandra Frey	Received

FRI-438	Histone deacetylase 5 methylation changes in mice and patients with Wilson disease	Valentina Medici	Received

THU-438	The presence of type 2 diabetes is independently associated with impairment of patient-reported outcomes in patients with non-alcoholic steatohepatitis	Zobair Younossi	Received

SAT-438	Effect of chondroitin sulfate in the rat liver cold ischemia and warm reperfusion injury	Maria Pierre	Received

FRI-439	Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation	Bogdan Procopet	Received

THU-439	Variability in liver function test results and the risk of heart disease and mortality: A nationwide population-based study	Su Jong Yu	Received

SAT-439	Identification of new drug targets to prevent ischemia-induced bile toxicity using a human biliary organoid model	Floris Roos	Received

FRI-440	Management of acute hepatic porphyria attacks in europe and united states: EXPLORE international, prospective, natural history study	Eliane Sardh	Received

SAT-440	Molecular fingerprint of T cell-mediated and antibody-mediated rejection after human liver transplantation	Richard Taubert	Received

THU-440	Changing incidence of reported hepatitis B and its different trends amongest age groups in china from 2004-2016	Mingyuan Zhang	Received

THU-441	Site-specific structural N-glycan alterations limit CD73 nucleotidase activity in human hepatocellular carcinoma	Karel Alcedo	Received

FRI-441	A novel heterozygous ABCB4, RUNDC3B and ABCB1 deletion associated with severe cholestatic liver disease in adults	Benedetta Terziroli Beretta-Piccoli	Received

FRI-442	Acute hepatic porphyria disease manifestations and daily life impacts in EXPLORE international, prospective, natural history study	Paolo Ventura	Received

THU-442	Role of drug transporters in the chemoresistance of hepatoblastoma	Maitane Asensio	Received

THU-443	Unexpected pro-tumorigenic effect of the chemokine Cxcl10 by modulation of tumor stroma in a murine model of HCC	Elisa Brandt	Received

FRI-443	Non-invasive fibrosis assessment in hyperferritinemia and hemochromatosis	André Viveiros	Received

THU-444	Alteration of miRNAs expression in patients with HCV-related cirrhosis who developed HCC after therapy with DAAs	Alessandra Brocca	Received

FRI-444	VTX-803 AAV-mediated correction of progressive familiar intrahepatic cholestasis type 3 in a clinically relevant mouse model	Nicholas D Weber	Received

FRI-445	Safety and efficacy of trientine treatment in Wilson disease in patients withdrawn from d-Penicillamine: Final results from a prospective study	Daphne van Scheppingen	Received

FRI-446	Reduction of hepatic Z-alpha1 antitrypsin by RNA interference prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model	Christine Wooddell	Received

THU-446	AMPK/PGC-1a-mediated metabolic reprogramming of hepatic stellate cells promote stemness of hepatocellular carcinoma via metabolite lactate shuttle	Jianye Cai	Received

THU-447	DNA damage response CHK2 activates senescence cellular program and supports oxidative metabolism to drive hepatocellular carcinoma development	Vinicio Carloni	Received

FRI-447	Clinical characteristics of liver cirrhosis and hepatocellular carcinoma occuring after Fontan operation	Jun Sik Yoon	Received

FRI-448	Correction of a metabolic liver disease after ex vivo gene editing of defective human primary hepatocytes	Mihaela Zabulica	Received

FRI-449	Complex ATP7B mutation patterns in Wilson disease and a evaluation of a yeast model for functional analysis of the individual variant	Donghu Zhou	Received

THU-451	Characterization of cholangiocarcinoma primary, circulating and metastatic stem-like cells	Margherita Correnti	Received

SAT-451	Gallbladder disease in the absence of cirrhosis is a significant risk factor for hepatocellular carcinoma	Kenda Al-Assi	Received

FRI-451	Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumour thrombus	Xiao Xiang	Received

FRI-452	Synergistic reduction of cancer proliferation and tumour growth in advanced murine hepatocellular carcinoma vis skewing and activation of innate and adoptive immunity	Muhammad Khan	Received

SAT-452	Analysis of intrahepatic sarcomatoid cholangiocarcinoma compared with intrahepatic adenocarcinoma	Yanghyon Baek	Received

THU-452	TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma	Cedric Coulouarn	Received

FRI-453	Rapamycin promotes tumoricidal immunity in murine HCC by inducing M1-type macrophages and dentritic cells polarization and enhancement of cytotoxic T-cells	Muhammad Khan	Received

SAT-453	Effects of sorafenib on pancreatic volume and their clinical implications in patients with hepatocellular carcinoma	LUCA IELASI	Received

THU-453	Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer	Carolin Czauderna	Received

SAT-454	Management of hepatocellular carcinoma in a real life multinational, longitudinal, observational study (TARGET-HCC)	Stephanie Watkins	Received

THU-454	Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma	Helena Degroote	Received

THU-455	Metabolomic analysis by 1H-nuclear magnetic resonance spectroscopy suggest that there are 2 phenotypes of human hepatocellular carcinoma developed in non-alcoholic fatty liver disease according to fibrosis level (F0F1 vs F3F4)	Aicha Demidem	Received

FRI-455	Effect of huaier granule on recurrence after curative resection of HCC: A multicenter, randomized clinical trial	Qian Chen	Received

FRI-456	MELD score is the only predictor for 30-day mortality in patients with ruptured hepatocellular carcinoma treated by emergent transarterial embolization	Ya-Ting Cheng	Received

THU-457	DoubleCortin/Like Kinase 1 (DCLK1) expression characterized specific cancer stem cell subpopulations of human cholangiocarcinoma primary cell cultures where its inhibition exerts anti-neoplastic effects	Sabina Di Matteo	Received

FRI-457	Comparative long-term outcomes of laparoscopic liver resection and radio frequency ablation for hepatocellular carcinoma: Location of tumor matters	Jai Young Cho	Received

SAT-457	Sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure	Tsung-Yi Cheng	Received

THU-458	Identification of relevant oncogenes in RAS-activated primary liver cancer using a targeted screening approach	Ursula Ehmer	Received

SAT-458	Subtraction arterial images of hepatocyte-specific contrast-enhanced MRI: Added value for the diagnosis of hepatocellular carcinoma in the liver imaging reporting and data system v2018	Sang Hyun Choi	Received

FRI-458	Response evaluation using modified RECIST criteria predict outcomes better than RECIST 1.1 criteria in patients with HCC treated with Yttrium-90 radioembolization	Hongjun Choi	Received

FRI-459	Prognostic performance of ten non-invasive liver function tests in patients with hepatocellular carcinoma submitted to transarterial chemoembolization	Pedro Costa-Moreira	Received

SAT-459	NASH as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role: Case-control study	Stefania De Lorenzo	Received

THU-459	Non-parenchymal TREM2 halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte proliferation	Ibone Labiano	Received

SAT-460	Influence of sustained virological response in diagnostic performance of alpha-fetoprotein for hepatocellular carcinoma in patients with HCV-cirrhosis	Ana Gómez	Received

THU-460	Longitudinal monitoring of cell-free DNA predicts for transarterial chemo-embolization failure in hepatocellular carcinoma	Joanne Evans	Received

FRI-460	What are the predictive factors for long-term survivors with advanced hepatocellular carcinoma treated with sorafenib?	Filipe de Sousa Damião	Received

FRI-461	Thermal ablation is a safe and effective treatment for intrahepatic cholangiocarcinoma in patients with cirrhosis	Álvaro Díaz-González	Received

THU-461	A diet-induced lean nonalcoholic steatohepatitis-associated hepatocellular carcinoma mouse model	Elizabeth Vlock	Received

SAT-461	HCC recurrence after DAA treatment in HCV patients	Maria Guarino	Received

SAT-462	Current non-invasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma	Shu Yein Ho	Received

FRI-462	A multicenter international study of sorafenib treatment in patients with hepatocellular carcinoma and chronic kidney disease undergoing hemodialysis	Álvaro Díaz-González	Received

THU-462	StARD1 is induced in human HCC and its overexpression aggravates cholesterol-mediated hepatocarcinogenesis in vivo	José Fernandez-Checa	Received

SAT-463	Albumin-bilirubin grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma	Shu Yein Ho	Received

THU-463	Role of natural killer cells receptors on the development and progression of hepatocellular carcinoma	Francesco Figorilli	Received

FRI-463	Long-term outcomes of irreversible electroporation for hepatocellular carcinoma	Elliot Freeman	Received

SAT-464	Predictive value of pretreatment neutrophil-to-lymphocyte ratio in survival of patients with hepatocellular carcinoma	Young Mi Hong	Received

THU-464	NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha	Beatrice Foglia	Received

FRI-464	Percutaneous microwave is better than radiofrequency ablation to obtain complete response in cirrhotic patients with very early and early hepatocellular carcinoma	Silvia Gaia	Received

THU-465	Variation of different histone deacetylases and the functional effects of HDAC inhibitors in hepatocellular carcinoma	Kim Freese	Received

SAT-465	The NIACE Score: A prognostic indicator in Hepatocellular carcinoma	William Kemp	Received

FRI-465	The INCRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model	Lika Gamaev	Received

THU-466	Epigenetic regulation of gene expression in a HCC-NASH murine model	Antonio Gil-Gómez	Received

FRI-466	A single centre experience of transarterial radioembolisation using Rhenium 188 for treatment of liver space occupying lesions	Jeffey George	Received

SAT-466	A meta-analysis of risk factors for intrahepatic and extrahepatic cholangiocarcinoma	Shahid Khan	Received

FRI-467	Optimal time-point of response assessment was associated with tumour burden in patients with unresectable hepatocellular carcinoma undergoing repeated transarterial chemoembolization	Guohong Han	Received

SAT-467	Pathologic identity of indeterminate hepatic nodules on dynamic computed tomography images of cirrhotic patients undergoing liver transplantation: A potential bias in evaluating suitability for transplantation	Ha Il Kim	Received

THU-467	Comparison of the immune tumour microenvironment between primary and metastatic hepatocellular carcinoma: Implication for biomarker research ofimmunotherapy	Chia-Wei Chen	Received

FRI-468	Identifying optimal candidates for combining transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma: A multicenter observational study	Guohong Han	Received

THU-468	SLU7 controls genome integrity: New role of truncated SRSF3 proteins	Maddalen Jimenez	Received

SAT-468	Prognostic value of post-treatment liver stiffness in hepatocellular carinoma with histologically confirmed cirrhosis	Jung Il Lee	Received

SAT-469	Frequency of TP53, CTNNB1, and TERT promoter mutations in patients with hepatocellular carcinoma from Southern Italy	Daniele Lombardo	Received

THU-469	Nanoparticular bisphosphonate to ively target and repolarize liver macrophages for efficient anti-tumour response	Leonard Kaps	Received

FRI-469	Vitamin K dosing could improve anti-cancer outcome of transarterial chemoembolization for patients with hepatocellular carcinoma-an open label, randomized, phase II study	Yoshimichi Haruna	Received

THU-470	The mRNA-binding protein tristetraprolin promotes hepatocarcinogenesis but inhibits tumour progression in liver cancer	Sonja Kessler	Received

SAT-470	Circulating levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of cholangiocarcinoma	Sven Loosen	Received

FRI-470	External beam radiotherapy as an effective and safe treatment in all stages of hepatocellular carcinoma with cirrhotic liver disease : A single institution experience	Clémence Hollande	Received

FRI-471	Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization	Chia-Wei Chen	Received

SAT-471	Hepatic adenomatosis increases risk of hepatic adenoma bleeding	Chelsea McDermott	Received

THU-471	Establishment of a short-termed orthotopic transplantation model in C57/B6 mice that recapitulates characteristic features of human intrahepatic cholangiocarcinoma	Theresa Wirtz	Received

FRI-472	ALBI grade determines survival of nivolumab-treated patients with advanced hepatocellular carcinoma: a real-world observational study	Yi-Hsiang Huang	Received

THU-472	Pharmacological inhibition of PIM1 suppresses tumor progression and enhances chemosensitivity in heptaocellular carcinoma	Ming Sum Leung	Received

SAT-472	Massive sequencing of circulating DNA as a potential tool for diagnosis and follow-up in patients with hepatocellular carcinoma	Beatriz Minguez	Received

FRI-473	Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study	Massimo Iavarone	Received

SAT-473	Transition to the era of direct-acting antiviral changes in the prognosis of patients with hepatitis C virus-related hepatocellular carcinoma	Yoshifumi Miura	Received

THU-473	Role of intracellular lysyl oxidase in progression of primary liver cancer	Monika Lewinska	Received

FRI-474	AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma	Massimo iavarone	Received

SAT-474	Misdiagnosis of focal liver lesions by means of CEUS	Tudor-Voicu Moga	Received

THU-474	Existence of intratumoral teriary lymphoid structures predicts better prognosis in Barcelona clinic of liver cancer stage 0-a hepatocellular carcinoma	Hui Li	Received

SAT-475	Clinical validation of the role of contrast-enhanced ultrasound in the EASL guidelines for the diagnosis of hepatocellular carcinoma	Lorenzo Mulazzani	Received

FRI-475	Experience impacts on reasons leading to sorafenib discontinuation and chance of long-term response	Ielasi Luca	Received

FRI-476	Repeated surgical resection versus radiofrequency ablation for recurrent hepatocellular carcinoma after surgical resection : A propensity score matching analysis	Chang Ke-Bin	Received

THU-476	Modeling cancer stem cell and differentiated cancer cell phenotypes in liver cancer organoids	Ruby Lieshout	Received

SAT-477	Impact of skeletal muscle quality and quantity on outcomes following curative therapy of hepatocellular carcinoma	Tomoaki Nakajima	Received

FRI-477	Factors associated with good post progression survival in post-sorafenib progressed advanced hepatocellular carcinoma patients not eligible for regorafenib	Chang Wook Kim	Received

THU-477	Sumoylation/acetylation drives forward oncogenic role of LKB1 in Liver	Fernando Lopitz Otsoa	Received

SAT-478	Comparison of prediction models for hepatocellular carcinoma development in treatment naive chronic hepatitis B patients with cirrhosis	Hyunwoo Oh	Received

THU-478	CXCL5 induced by transforming growth factor-beta and Axl signalling causes neutrophil extracellular trap formation in hepatocellular carcinoma	Wolfgang Mikulits	Received

FRI-478	Survival outcomes of TACE in treatment-naive and recurrent HCC after curative resection: A propensity score-matched analysis	David Sooik Kim	Received

THU-479	The hepatocyte specific role of the NRF2/KEAP1 axis for HCC Progression during chronic liver disease	Antje Mohs	Received

FRI-479	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?	Jihye Kim	Received

SAT-479	Analysis of the relationship between serum creatinine/cystatin C ratio and muscle mass in patients with hepatocellular carcinoma	Hirotaka Oura	Received

SAT-480	Long-term survivors in patients with hepatocellular carcinoma: An ITA.LI.CA report	Filippo Pelizzaro	Received

THU-480	Imaging mechanical stiffness and molecular landscapes of cancer stem cell niches in human hepatocellular carcinomas	Orlando Musso	Received

SAT-481	Intratumoral mast cell infiltration and recurrence of hepatocellular carcinoma in patients undergoing orthotopic liver transplantation	Nataliya Rohr-Udilova	Received

THU-481	Classification of intrahepatic cholangiocarcinoma microenvironment based on immune cell and tumor stromal features	Hiep Nguyen Canh	Received

SAT-482	Incidence of hepatocellular carcinoma after hepatitis C cure with DAA in a cohort of patients with advanced liver disease: Results from a prospective screening program	Marco Sanduzzi Zamparelli	Received

THU-482	A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma	Barbara Oliviero	Received

FRI-482	Ideal number of lymph nodes to harvest for intrahepatic cholangiocarcionoma	Sung Hyun kim	Received

SAT-483	Hepatic epithelioid hemangioendotelioma: An international multicenter study	Marco Sanduzzi Zamparelli	Received

THU-483	Blood based weighted gene co-expression network analysis identifies miRNA prognostic biomarkers for HCC	Devis Pascut	Received

FRI-483	Endoscopic biliary drainage in patients with cholangiocarcinoma: Polyethylene versus self-expanding metal stents	Martha M. Kirstein	Received

FRI-484	The early clinical response at 2 weeks of lenvatinib therapy for patients with advanced HCC	Teiji Kuzuya	Received

SAT-484	CEUS pattern of hepatocellular carcinoma: Prognostic implication	Vito Sansone	Received

THU-484	Mass spectrometric analysis of serum haptoglobin fucolysation in patients stratified according to fibrosis stages, and the presence of hepatocellular carcinoma	Valentina Peta	Received

THU-485	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma	David James Pinato	Received

FRI-485	Laparoscopic liver resection vs. Percutaneous radiofrequency ablation for small single nodular HCC: Comparison of treatment outcome	Dong Ho Lee	Received

SAT-485	European cholangiocarcinoma (EU-CCA) registry: An initiative to broaden awareness on the second most common primary liver cancer	Alvaro Santos-Laso	Received

THU-486	A pro-regenerative environment triggers premalignant to malignant transformation and pinpoints new therapeutic targets	Anna Potapova	Received

SAT-486	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma	Bernhard Scheiner	Received

FRI-486	Serum cytokines and chemokines correlated with tumor recurrrence and survival after surgical resection for overt and occult HBV-related hepatocellular carcinoma	I-Cheng Lee	Received

SAT-487	Reliability of a single biopsy in evaluating immune tumor microenvironment of hepatocellular carcinoma	Ying-Chun Shen	Received

THU-487	Circulating MIR-4492 as a biomarker to predict therapy response and disease free survival in hepatocellular carcinoma	Muhammad Yogi Pratama	Received

FRI-487	A new prognosis prediction model in patients with hepatocellular carcinoma after Yttrium-90 radioembolization	Jae Seung Lee	Received

FRI-488	Prognostic value of tumor markers after a complete response to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma following curative resection	Jae Seung Lee	Received

THU-488	Acquisition of stem-like features in cholangiocarcinoma is associated with an oxidative metabolism	Chiara Raggi	Received

SAT-488	Both ALBI/delta ALBI grade are good predictive parameters for prognosis in chc/hcc patients with transarterial chemoembolization treatment	Wei Teng	Received

THU-489	Mixed HCC-ICC liver cancer derives from hepatic progenitor cells: A lineage tracing investigation in a mouse liver inflammation model	NOFAR ROSENBERG	Received

FRI-489	Downstaging by 90-yttrium radioembolization of unresectable locally advanced hepatocellular carcinoma: A single center experience	Carolina Martelletti	Received

SAT-489	Efficacy and safety of thermal ablation in patients with hepatocellular carcinoma and high comorbidity	Maria Torner Simó	Received

THU-490	Liver NK cells from NLG4 KO mice inhibit progressions of hepatocellular carcinoma of C57BL/6 mice model through decrease in p53 and AKT expressions	Johnny Amer	Received

SAT-490	No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort	Anais Vallet-Pichard	Received

FRI-490	The real world practice of systemic therapies in patients with advanced hepatocellular carcinoma in Japan: what has changed since lenvatinib approval?	Susumu maruta	Received

THU-491	The role of alanine glyoxylate aminotransferase in hepatocellular carcinoma	Letizia Satriano	Received

SAT-492	Associating spleen volume and liver stiffness measurements improves prediction of persistent post-hepatectomy decompensation after resection of hepatocellular carcinoma	Ramiro Manuel Fernandez Placencia	Received

THU-492	Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma	Ulrich Spengler	Received

FRI-492	Long-term outcome according to initial treatment modality in multiple hepatocellular carcinoma within the Milan criteria	Joo Hyun Oh	Received

THU-493	Reciprocal changes in ARID1A and EZH2 are associated with cholangiocarcinoma development in a mouse model of caroli disease with high Yap expression	Luca Fabris	Received

SAT-493	Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma	Luca Vigano	Received

FRI-493	Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocelluar carcinoma	Takuya Okamoto	Received

FRI-494	Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis	Andy Thompson	Received

SAT-494	Global hepatocellular carcinoma mortality trends: An analysis of the world health organization cancer mortality database	Robert Wong	Received

THU-494	MicroRNA-96 in non-B non-C hepatocellular carcinoma	Takeshi Matsui	Received

SAT-495	Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the US	Ming Yang	Received

FRI-495	Post transarterial chemoembolization fever can predict poor survival in patients with TNM stage I hepatocellular carcinoma	Chien-Wei Peng	Received

THU-496	Real-time, intravital imaging of diethylnitrosamine-induced hepatocellular carcinoma	Alexandra Thompson	Received

SAT-496	Circulating cell-free HBV-human chimera DNA as new marker for HCC recurrence and clonality after curative resection	Shiou-Hwei Yeh	Received

FRI-496	Recurrence of hepatocellular carcinoma in patients with complete response treated with direct acting antivirals in clinical practice	Christie Perello	Received

THU-497	Molecular fingerprint of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	Roger Esteban-Fabró	Received

SAT-497	Individual surveillance using PAGE-B score-based hepatocellular carcinoma risk in chronic hepatitis B patients under potent antiviral therapy	Minjong Lee	Received

FRI-497	Shifting to sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: A real world experience	Po-Ting Lin	Received

THU-498	Mass-spectrometric analysis of deregulated proteins in gallbladder carcinoma	Felicia Truckenmueller	Received

FRI-498	A current status of therapeutic choice and feasibility for hepato cellular carcinoma patients over 70 years old	Seoung Yoon Rho	Received

FRI-499	Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040	Frank DeRosa	Received

THU-499	Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein	Yuki Tsuji	Received

THU-500	EGFR is a preventative target for NASH-induced liver cancer	Atsushi Umemura	Received

FRI-500	Sorafenib for recurrent hepatocellular carcinoma after liver transplantation: Intrinsic resistance or not?	Vito Sansone	Received

FRI-501	Survival among patients with advanced hepatocellular carcinoma in the pre-TKI versus TKI eras	Miyuki Sensui	Received

THU-501	Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model	Sanne Van Campenhout	Received

FRI-502	Factors impacting survival in a large cohort of patients with unresectable hepatocellular carcinoma treated with Y-90 resin microspheres at a single centre	Naomi Ruff	Received

THU-502	ZEB1 expression in myofibroblasts regulates their interaction with cholangiocarcinoma cells promoting tumour progression	Javier Vaquero	Received

THU-503	Macrophage migration inhibitory factor shows a pro-proliferative and anti-apoptotic effect on hepatoma cells in vitro and promotes tumour growth in vivo	Theresa Wirtz	Received

FRI-505	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting	Takuya Sho	Received

FRI-506	A nationwide multicenter study in Japanese patients treated with lenvatinib in real world practice	Kaoru Tsuchiya	Received

FRI-507	Hepatocyte-specific role of c-Jun N-terminal kinase 2 for disease progression and therapy in chronic liver disease	Marius Woitok	Received

The International Liver Congress 2019

10-14 April 2019 Vienna

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 10/04/2019 TO 10/04/2021

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.ILC2019.2019



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access